

# Reduced adipocyte glutaminase activity promotes energy expenditure and metabolic health

Received: 2 December 2022

Accepted: 14 June 2024

Published online: 15 July 2024

 Check for updates


Simon Lecoutre <sup>1,2,12</sup>, Salwan Maqdasy <sup>1,12</sup>, David Rizo-Roca <sup>3,12</sup>, Gianluca Renzi<sup>1</sup>, Ivan Vlassakev<sup>1</sup>, Lynn M. Alaeddine <sup>1</sup>, Romane Higos<sup>1</sup>, Jutta Jalkanen <sup>1</sup>, Jiawei Zhong <sup>1</sup>, Danae S. Zareifi <sup>1</sup>, Scott Frendo-Cumbo <sup>1</sup>, Lucas Massier <sup>1</sup>, Ondrej Hodek <sup>4</sup>, Marta Juvany<sup>4</sup>, Thomas Moritz<sup>4,5</sup>, Thais de Castro Barbosa <sup>1</sup>, Muhmmad Omar-Hmeadi <sup>1</sup>, Marta López-Yus <sup>6,7,8</sup>, Fatiha Merabtene<sup>2</sup>, Jimon Boniface Abatan<sup>2</sup>, Geneviève Marcelin<sup>2</sup>, Elie-Julien El Hachem <sup>2</sup>, Christine Rouault<sup>2</sup>, Martin O. Bergo<sup>9</sup>, Paul Petrus <sup>1</sup>, Juleen R. Zierath <sup>3,10</sup>, Karine Clément <sup>2,11</sup>, Anna Krook <sup>3</sup>, Niklas Mejhert <sup>1,13</sup>  & Mikael Rydén <sup>1,13</sup> 

Glutamine and glutamate are interconverted by several enzymes and alterations in this metabolic cycle are linked to cardiometabolic traits. Herein, we show that obesity-associated insulin resistance is characterized by decreased plasma and white adipose tissue glutamine-to-glutamate ratios. We couple these stoichiometric changes to perturbed fat cell glutaminase and glutamine synthase messenger RNA and protein abundance, which together promote glutaminolysis. In human white adipocytes, reductions in glutaminase activity promote aerobic glycolysis and mitochondrial oxidative capacity via increases in hypoxia-inducible factor 1 $\alpha$  abundance, lactate levels and p38 mitogen-activated protein kinase signalling. Systemic glutaminase inhibition in male and female mice, or genetically in adipocytes of male mice, triggers the activation of thermogenic gene programs in inguinal adipocytes. Consequently, the knockout mice display higher energy expenditure and improved glucose tolerance compared to control littermates, even under high-fat diet conditions. Altogether, our findings highlight white adipocyte glutamine turnover as an important determinant of energy expenditure and metabolic health.

Obesity-associated insulin resistance and type 2 diabetes are characterized by changes in the circulating levels of multiple amino acids<sup>1–4</sup>. Targeted restorations in some of these metabolites improve metabolic health, indicating that they are more than mere biomarkers of disease. For example, brown adipose tissue (BAT) activation in mice increases the consumption of branched-chain amino acids and thereby protects against their insulin resistance-promoting effects<sup>5,6</sup>. In humans living with obesity and insulin resistance, several amino acids and their

derivatives are altered in white adipose tissue (WAT)<sup>7</sup>. However, the mechanism(s) by which disturbances in white adipocyte amino acid metabolism contribute to metabolic disorders is not fully understood.

Glutamine and glutamate are essential components in numerous cellular processes, encompassing nucleotide and glutathione biosynthesis, tricarboxylic acid cycle (TCA) anaplerosis and transcriptional regulation via epigenetic modifications<sup>8</sup>. These polar amino acids are interconverted by multiple enzymes and their respective

A full list of affiliations appears at the end of the paper.  e-mail: [niklas.mejhert@ki.se](mailto:niklas.mejhert@ki.se); [mikael.ryden@ki.se](mailto:mikael.ryden@ki.se)

levels serve as biomarkers of type 2 diabetes risk, where a high plasma glutamine-to-glutamate ratio is protective in both humans and mice<sup>9,10</sup>. In healthy participants, WAT is an important contributor to this circulating ratio through the release of glutamine and the uptake of glutamate<sup>11</sup>. It is therefore conceivable that perturbations in WAT glutamine and glutamate turnover induced by obesity may contribute to the development of metabolic disorders.

Herein, we investigated how white adipocyte glutamine metabolism affects metabolic health. By combining clinical and experimental studies, we demonstrate that glutamine to glutamate conversion (glutaminolysis) in white adipocytes is increased in people with versus without obesity and insulin resistance. Genetic reduction and pharmacologic inhibition of glutaminase (GLS) in white adipocytes increases the glutamine-to-glutamate ratio and improves glucose tolerance in vivo by rewiring intracellular metabolism and elevating energy expenditure.

## Results

### Glutamine-to-glutamate ratios are linked to insulin resistance

We set out to systematically determine the relationship between obesity-induced insulin resistance and glutamine-to-glutamate stoichiometry in the circulation and WAT. For this, we collected plasma and subcutaneous WAT samples from women with and without obesity exhibiting different degrees of insulin sensitivity as determined by hyperinsulinaemic euglycemic clamps (clinical characteristics are provided in Supplementary Table 1). As expected, our mass spectrometry-based analyses revealed that plasma branched-chain (valine, leucine and isoleucine) and aromatic (tyrosine and phenylalanine) amino acids were negatively associated with glucose disposal rate, while serine, asparagine and glycine displayed positive correlations (Fig. 1a)<sup>2,12</sup>. These findings demonstrate that our measures are accurate, and that the cohort recapitulates known biology. By mining the data further, we noticed that the circulating glutamine and glutamate levels displayed reciprocal relationships where the glutamine-to-glutamate ratio was strongly associated with insulin sensitivity (Fig. 1a). When comparing with the corresponding levels in WAT, we found the glutamine-to-glutamate ratio in the two compartments to be closely correlated (Fig. 1a). Furthermore, in women with versus without obesity, the plasma and WAT glutamine-to-glutamate ratios were decreased, and the latter was associated with waist-to-hip ratio and fat cell volume: two independent measures of metabolic health (Fig. 1b,c and Extended Data Fig. 1a). Altogether, our results indicate that the subcutaneous WAT glutamine-to-glutamate ratio reflects circulating levels and is linked to alterations in fat mass distribution and insulin sensitivity.

### GLS and *GLUL* levels associate with insulin resistance and energy expenditure

The glutamine-to-glutamate ratio in WAT could either reflect plasma concentrations or altered metabolism of these amino acids directly

within the tissue. As the interconversion of glutamine and glutamate is controlled by several enzymes<sup>13</sup>, we determined whether genes encoding proteins involved in this turnover were altered in the obese, insulin resistant state. Quantitative PCR (qPCR) measurements based on isolated mature human fat cells from 22 women and six men (clinical characteristics in Supplementary Table 1), revealed that glutamine synthase (*GLUL*) was lower and *GLS* was higher comparing cells from participants with versus without obesity (Fig. 1d). Given that the levels of the other investigated genes were unaffected, this alteration in stoichiometry was unique and suggested increased glutaminolysis in people living with obesity. This notion was corroborated (1) in a replication cohort comprising men and women<sup>14</sup> (Extended Data Fig. 1b), (2) at the protein level by western blot (Fig. 1e) and (3) with enzyme activity assays (Fig. 1f). To validate these findings further, we measured *GLS* and *GLUL* messenger RNA (mRNA) expression in subcutaneous WAT from women displaying a broad range in body weight and insulin sensitivity<sup>15</sup>. We found inverse associations between these genes and multiple clinical parameters including body mass index, energy expenditure and insulin sensitivity at the whole-body and fat cell level (Fig. 1g). Altogether, this suggests that obesity-induced increases in WAT glutaminolysis are linked to attenuated energy expenditure and insulin sensitivity.

### TNF promotes *GLS* expression via the JNK-c-Jun pathway

We next set out to identify factors that regulate *GLS* and *GLUL* expression in fat cells. For this, we first identified pathways correlating with the *GLUL*-to-*GLS* ratio in human WAT from 56 women with or without obesity<sup>15</sup>. Our analyses revealed pro-inflammatory processes to be highly enriched (Extended Data Fig. 2a). By measuring secretion of the pro-inflammatory cytokine TNF from WAT pieces in the same cohort, we confirmed a negative correlation between the *GLUL*-to-*GLS* ratio and TNF levels (Extended Data Fig. 2b). To test for causality, we incubated adipocytes in the presence or absence of recombinant TNF. Compared to non-stimulated cells, TNF treatment increased *GLS* and concomitantly reduced *GLUL* mRNA levels, changes that were paralleled by a reduction of the glutamine-to-glutamate ratio (Extended Data Fig. 2c). Given that TNF increases lipolysis<sup>16</sup>, we also assessed the effects of two other regulators of lipid turnover, insulin and isoprenaline, on *GLS* and *GLUL* expression. However, incubations with these factors did not affect the mRNA levels of the two genes indicating that the effects of TNF were independent of its action on lipid metabolism (Extended Data Fig. 2d). Next, we dissected the intracellular signalling events linking TNF to glutamine metabolism. As shown in Extended Data Fig. 2e, incubation with inhibitors targeting signal transducer and activator of transcription 3 (STAT3), nuclear factor- $\kappa$ B and c-Jun N-terminal kinase (JNK), revealed that only the latter abrogated the effects of TNF on *GLS* protein levels. In human breast cancer cells, JNK has been shown to regulate glutaminolysis by promoting binding of the transcription factor c-Jun to the promoter region of *GLS*<sup>17</sup>. We therefore performed chromatin

**Fig. 1 | Adipose glutaminolysis is increased in obesity-induced insulin resistance.** **a**, Correlations between amino acid levels in plasma and insulin sensitivity (left), amino acid levels in WAT and insulin sensitivity (middle) and between amino acid levels in plasma ( $n = 53$ ) and WAT ( $n = 26$ ) (right) in cohort 1. Insulin sensitivity was measured by hyperinsulinaemic euglycaemic clamp expressed as glucose disposal rate corrected for mean plasma insulin levels at steady state (M/I). Associations were calculated using Spearman's rank correlation. **b**, The plasma ( $n = 53$ ) (left) and WAT ( $n = 26$ ) (right) glutamine-to-glutamate (gln to glu) ratios in cohort 1 comparing women living without (w/o) or with obesity (BMI  $\geq 30$  kg m<sup>-2</sup>). Groups were compared using Student's *t*-test. **c**, The correlation between WAT glutamine-to-glutamate ratios and waist-to-hip ratio (left) or fat cell volume (right) in cohort 1 ( $n = 26$ ). Pearson's correlation coefficients are shown. **d**, Expression of genes encoding glutamine-glutamate (gln-glu) metabolizing proteins measured by qPCR in isolated fat cells from cohort 2. Results are displayed according to biological pathways and compared for people living w/o ( $n = 12$ ) or with ( $n = 16$ ) obesity. Groups were


compared using Student's *t*-test or the Mann-Whitney *U*-test, depending on the distribution. **e**, Protein levels of *GLS* and *GLUL* in subcutaneous white adipocytes from participants living w/o ( $n = 4$ ) or with ( $n = 3$ ) obesity (cohort 2). Proteins derived from the same samples were loaded on two different gels. **f**, *GLS* activity in subcutaneous adipocytes from participants living w/o ( $n = 7$ ) or with ( $n = 8$ ) obesity in cohort 2. Groups were compared using Student's *t*-test. **g**, Correlations between indicated clinical and adipocyte parameters and *GLUL* or *GLS* expression in bulk transcriptomic data of subcutaneous WAT from cohort 3 ( $n = 56$ ). All correlations were significant ( $P < 0.05$ ), circle sizes are proportional to the Pearson's correlation coefficient and the colour indicates positive (pos.) (green) or negative (neg.) (purple) associations. Data in **b**, **d** and **f** show mean  $\pm$  s.e.m. Relevant *P* values are shown. asp-asn, aspartate to asparagine conversion; energy exp., energy expenditure by indirect calorimetry corrected for body weight (kcal kg<sup>-1</sup> day<sup>-1</sup>); GMP, guanosine monophosphate; ins-stim. lipog., log<sub>10</sub> maximal insulin-stimulated lipogenesis in isolated mature fat cells.


immunoprecipitation followed by qPCR and observed an enrichment of c-Jun in the *GLS* promoter following TNF stimulation (Extended Data Fig. 2f). Taken together, we show that TNF transcriptionally regulates *GLS* levels through the JNK-c-Jun pathway.

### Glutaminolysis perturbations alter energy metabolism gene sets

To understand how altered glutamine turnover affects white fat cell function, we targeted *GLS*, which encodes the rate-limiting enzyme in glutaminolysis<sup>8</sup>. By electroporating human adipocytes with small-interfering RNA (siRNA) duplexes, we efficiently reduced GLS

mRNA and protein levels (Fig. 2a), resulting in decreased GLS activity (Fig. 2b) and increased glutamine-to-glutamate ratio (Fig. 2c). These effects were not secondary to alterations in adipogenesis as the treatment did not affect adipocyte marker mRNA and protein levels, endocrine function or lipid content (Extended Data Fig. 3a–c). By performing RNA sequencing and pathway analyses in *GLS*-depleted versus control adipocytes, we found no clear patterns among down-regulated genes. However, multiple metabolic gene sets, for example, oxidative phosphorylation, TCA cycle and fatty acid oxidation, were upregulated in si*GLS* adipocytes (Fig. 2d,e and Extended Data Fig. 3d,e). To analyse our data in more detail, we used ProfAT that quantifies





**Fig. 2 | Reduced GLS activity promotes thermogenic gene expression in adipocytes.** **a**, GLS mRNA and protein levels in human adipocytes transfected with non-silencing (siC) or GLS-targeting (siGLS) oligonucleotides. Data for mRNA are expressed relative to siC and were compared using Student's *t*-test (eight replicates per condition, repeated more than three times). A representative western blot of GLS protein is shown (repeated more than three times). GAPDH was used as a loading control. **b,c**, Comparisons of siC and siGLS adipocytes displaying GLS enzyme activity (four replicates per condition, repeated more than three times) and glutamine (gln) and glutamate (glu) levels including glutamine-to-glutamate ratio (eight replicates per condition, repeated more than three times) (**c**). Data were compared using Student's *t*-test. **d,e**, RNA sequencing data comparing siC and siGLS-treated human adipocytes (three replicates per condition). Data are presented as a volcano plot of all genes (**d**) and a heatmap of changes in the expression of cellular respiration

genes (**e**). **f**, Probability of BAT- or WAT-like transcriptomic profiles in human adipocytes transfected with siC or siGLS oligonucleotides. The score is based on ProFAT<sup>18</sup>, which quantifies the thermogenic potential from gene expression datasets. **g**, ETC, uncoupling protein 1 (UCP1) and GLS protein levels in human adipocytes transfected with siC or siGLS oligonucleotides (repeated more than three times). Proteins from the same experiment were loaded on three different gels run in parallel. **h**, Representative images of UCP1 and cytochrome C oxidase (COX4) immunofluorescence in human adipocytes transfected with siC or siGLS oligonucleotides (repeated three times). Scale bar, 20  $\mu$ m. **i**, Representative examples of GLS, ETC, UCP1 and LAMIN A/C protein levels in human adipocytes engineered to overexpress GLS on doxycycline (doxy) incubation. Data show comparisons of non-induced versus induced cells (repeated twice). Data **a–c** show mean  $\pm$  s.e.m. Relevant *P* values are shown.


the thermogenic potential from transcriptomic data<sup>18</sup>. This revealed that *GLS* depletion increased the expression of genes linked to thermogenesis and substrate use (Fig. 2f), including components of the electron transport chain (ETC) and uncoupling protein 1 (UCP1), effects that were also observed at the protein level (Fig. 2g,h). To validate and extend these results, we used several orthogonal approaches. First, we observed effects on ETC protein levels by altering glutamine concentrations in the media (Extended Data Fig. 3f). Second, in rescue experiments, we reversed the siGLS phenotype by incubating the cells with  $\alpha$ -ketoglutarate (a cell-permeable analogue of the glutamate derivative  $\alpha$ -ketoglutarate to restore TCA anaplerosis) or by re-expressing GLS (Extended Data Fig. 3g–h). Third, we generated human adipocytes with doxycycline-inducible *GLS* expression. In these cells, incubations with doxycycline resulted in marked *GLS* induction with concomitant reductions in UCP1 and ETC proteins (Fig. 2i). Collectively, this suggests that perturbations of human adipocyte glutaminolysis affect the expression of genes involved in substrate use and bioenergetic pathways.

### Reduced GLS activity increases oxidative metabolism

To assess the functional implications of the observed transcriptional reprogramming, we measured basal and maximal oxygen consumption rates (OCR). Consistent with our findings at the mRNA and protein levels, siGLS versus siC adipocytes displayed elevated basal and maximal OCR demonstrating that mitochondrial respiration was increased (Fig. 3a). These effects required UCP1 and were phenocopied by glutamine depletion (Extended Data Fig. 4a,b). To determine substrate preference, we performed mitochondrial fuel flex tests in the basal

energetic state. For this, we treated cells with etomoxir (a carnitine palmitoyl transferase 1 inhibitor) or UK5099 (a mitochondrial pyruvate carrier inhibitor). Our data revealed that while both fatty acids and glucose were metabolized at higher rates in siGLS adipocytes compared to control cells, glucose was the major energy source (Fig. 3b). In line with this observation, we found that siGLS versus siC cells displayed increased uptake of glucose (Fig. 3c), elevated intracellular levels of several glucose-derived metabolites (Fig. 3d) and increased glycolytic activity as measured by the extracellular acidification rate (ECAR) (Fig. 3e). By incubating the cells with [<sup>13</sup>C<sub>6</sub>] glucose, we confirmed these results as the label was incorporated to a higher degree into pyruvate, secreted lactate and TCA intermediates in *GLS*-depleted compared to control cells (Fig. 3f–h). To test whether the increased OCR in siGLS adipocytes was dependent on glucose metabolism, we depleted the cells of extracellular glucose, inhibited glycolysis with 2-deoxy-glucose or suppressed mitochondrial pyruvate oxidation using UK5099. Under all these conditions, the phenotype of *GLS*-depleted cells was reversed (Extended Data Fig. 4c–e). Conversely, incubations with pyruvate amplified OCR in both siC and siGLS cells (Extended Data Fig. 4f). These findings suggest that mitochondrial activation on *GLS* depletion is characterized by increased glucose catabolism.

In addition to genetically reducing *GLS* levels, we performed short-term experiments following *GLS* inhibition with bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Mass spectrometry-based analyses confirmed that BPTES-treated adipocytes displayed reduced glutamine conversion (determined as <sup>13</sup>C-glutamine incorporation) and increased intracellular levels of multiple glycolytic



**Fig. 3 | Adipocyte GLS inhibition promotes glucose utilization and oxidative metabolism.** **a**, OCRs during mitostress tests in siC (black) or siGLS (green) human adipocytes (left). Data (12 replicates per condition, experiment repeated at least three times) were compared for basal respiration and maximal respiratory capacity using Student's *t*-test (right). **b**, Metabolic fuel flex tests in siC or siGLS human adipocytes. Data (12 replicates per condition from more than three experiments) displaying the drop in OCR from baseline after drug injection (UK5099 in left or etomoxir in right) were calculated and compared using Student's *t*-test. **c**, Glucose uptake in human adipocytes transfected with siC or siGLS (four replicates per condition, repeated twice). Data were compared using Student's *t*-test. **d**, Intracellular levels of glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), pyruvate and lactate in human adipocytes transfected with


siC or siGLS (six replicates per condition). Data were compared using Student's *t*-test. **e**, ECAR during glycostress tests in siC or siGLS human adipocytes (left). Data (12 replicates per condition, repeated more than three times) were compared for glycolysis and glycolytic (gly.) capacity (right) using Student's *t*-test. **f–h**, Glucose-<sup>13</sup>C incorporation in pyruvate (**f**), secreted lactate (**g**) and TCA intermediates (**h**) in human adipocytes transfected with siC or siGLS (seven replicates per condition). Data were compared using Student's *t*-test. Data in all panels show mean  $\pm$  s.e.m. Relevant *P* values are shown. 2DG, 2-deoxy-D-glucose;  $\alpha$ -KG, alpha-ketoglutarate; FCCP, carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone; G, glucose; norm., normalized; O, oligomycin; R/A, rotenone/antimycin A; rel., relative.

metabolites, ETC protein levels, OCR and ECAR (Extended Data Fig. 5a–e) compared to control cells. Similar effects on mitochondrial gene expression and protein abundance were observed with the GLS inhibitor telegenastat (CB-839) (Extended Data Fig. 5f, g). Thus, both genetic and pharmacologic reductions in glutaminolysis promote glycolytic and oxidative activity in adipocytes.

### HIF1 $\alpha$ promotes glycolysis following GLS depletion


We hypothesized that altered glutaminolysis in adipocytes is linked to the transcriptional rewiring of metabolism through intracellular protein O-GlcNAcylation<sup>7</sup> or by altered expression of the histone lysine methyltransferase PR/SET domain 9 (encoded by *PRDM9*)<sup>19</sup>. However, we found no discernible changes in O-GlcNAcylation comparing siGLS versus siC cells (Extended Data Fig. 6a) and *PRDM9* was undetectable in our cell model (Extended Data Fig. 6b). Next we determined whether hypoxia-inducible factor 1 $\alpha$  (HIF1 $\alpha$ ), adenosine monophosphate-activated protein kinase (AMPK) or mammalian

target of rapamycin complex 1 (mTORC1) promoted the observed phenotype as these proteins are established regulators of energy metabolism<sup>20–22</sup>. While the activities of AMPK and mTORC1 appeared unaffected (Extended Data Fig. 6c), we observed an increase in the expression of HIF1 $\alpha$  target genes in GLS-depleted versus control cells (Fig. 4a). To follow up on this, we confirmed that HIF1 $\alpha$  protein levels were upregulated following GLS inhibition (Fig. 4b). We reasoned that this could be secondary to reductions in  $\alpha$ -ketoglutarate, as this metabolite is a substrate for proline hydroxylation and subsequent degradation of HIF1 $\alpha$  (Fig. 4c)<sup>23</sup>. Accordingly, we observed a reduction in alpha-ketoglutarate levels in GLS-depleted cells (Fig. 4d), and supplementation with eta-ketoglutarate attenuated the increase in HIF1 $\alpha$  in cells with reduced GLS activity (Fig. 4b). HIF1 $\alpha$  has been shown to promote glycolytic activity<sup>24</sup>. In line with this, we observed that eta-ketoglutarate supplementation or HIF1 $\alpha$  inhibition (using inhibitor VI) abrogated the increase in ECAR following GLS depletion (Fig. 4e, f). Both these treatments also reversed the elevated OCR observed in



**Fig. 4 | HIF1α promotes glycolysis following adipocyte GLS depletion.** **a**, Heatmap of HIF1α target genes altered in siGLS versus siC treated human adipocytes (three replicates per condition). **b**, Effects of CB-839 in human adipocytes on protein levels of HIF1α. Effects of eta-ketoglutarate (EtaKG) or the HIF1α inhibitor VI (Inhib. VI) are shown (repeated twice). **c**, Illustration of how alpha-ketoglutarate (α-KG) degrades HIF1α through prolyl hydroxylase domain (PHD) proteins. **d**, Relative levels of α-KG in siGLS (*n* = 7) versus siC (*n* = 6) human adipocytes (repeated twice). Data were compared using Student's *t*-test. **e**, Normalized (norm.) basal ECAR during glycostress tests in siC or siGLS human adipocytes treated with EtaKG (11 replicates per condition, repeated twice). Data were compared using two-way analysis of variance (ANOVA) and Tukey's post hoc test. **f**, Normalized basal ECAR rate during glycostress tests in siC or siGLS human adipocytes treated with the HIF1α inhibitor VI (12 replicates per condition, repeated twice). Data were compared using two-way ANOVA and Tukey's post hoc test. **g**, Normalized OCR in siC or siGLS human adipocytes treated with or without the HIF1α inhibitor VI (left) (six replicates per condition, repeated two times). Data were compared for basal respiration and maximal respiratory capacity

using two-way ANOVA and Tukey's post hoc test (right). **h**, Lactate secretion in human adipocytes transfected with siC (*n* = 7) or siGLS (*n* = 7) (left) or treated with DMSO (*n* = 6) or CB-839 (*n* = 7) (right). Data were compared using Student's *t*-test (repeated more than three times). **i, j**, Representative western blots of total and phosphorylated protein levels of p38 MAPK, CREB and ATF2 in human adipocytes transfected with siC or siGLS (**i**) or incubated with DMSO or BPTES (**j**, repeated twice). Proteins from the same experiment were loaded on four different gels in parallel for **i, j**. **k**, Representative western blots of total and phosphorylated protein levels of p38 MAPK, ATF2 as well as ETC proteins in human adipocytes incubated with or without lactate (for 30 min) and the p38 MAPK inhibitor SB203580 (pretreatment for 2.5 h) (repeated twice). Proteins from the same experiment were loaded on five different gels in parallel. **l**, Representative western blot showing the ETC and GLS protein levels in siC or siGLS human adipocytes treated with or without the p38 MAPK inhibitor SB203580 (experiment repeated twice). **m**, Model of how inhibition of glutaminolysis drives a metabolic reprogramming promoting adipocyte thermogenesis. Data **d–h** show mean ± s.e.m. Relevant *P* values are shown. **c, m**, Created with BioRender.com.



**Fig. 5 | Pharmacological GLS inhibition in male and female mice reduces fat mass and induces adipocyte *Ucp1* expression in inguinal WAT.** **a**, Body weight changes in male and female mice fed chow (CD) ( $n = 9$  for each gender) or a HFD, treated either with vehicle ( $n = 12$  for each gender) or with 200 mg kg<sup>-1</sup> of CB-839 ( $n = 12$  males and  $n = 10$  females) administered daily by gavage for 19 days. Data were analysed by two-way ANOVA and Tukey's post hoc test. **b**, The weights of one pad out of the two pads of inguinal (iWAT), one pad out of the two pads of epigonadal (eWAT) and mesenteric (mWAT) WAT as well as BAT were measured in the male and female mice described in **a**. Data were analysed by one-way ANOVA and Tukey's post hoc test. **c**, *Ucp1* gene expression profiles were analysed in

iWAT samples obtained from the male and female mice described above. Data are presented as min–max (median) and were compared using non-parametric (Kruskal–Wallis) one-way ANOVA. **d**, The circulating levels of insulin were measured and the Homeostatic Model Assessment–Insulin Resistance (HOMA-IR) index was calculated in male and female mice fed CD ( $n = 9$  males and  $n = 8$  females) or HFD, treated either with vehicle ( $n = 12$  for each gender) or with CB-839 ( $n = 12$  males and  $n = 10$  females) as described above. Data were analysed by one-way ANOVA and Dunnett's post hoc test. Data in **b** and **d** show mean  $\pm$  s.e.m. The *P* values are displayed only for the comparison between HFD treated with either vehicle or CB-839.

siGLS cells (Fig. 4g and Extended Data Fig. 6d). Taken together, our results indicate that reductions in GLS activity affect HIF1 $\alpha$  stability, via lowered  $\alpha$ -ketoglutarate levels, and that this step is required for the observed increases in glycolysis and mitochondrial activity.


### GLS depletion promotes mitochondrial activity via p38 MAPK

Next, we investigated how reduced GLS activity in adipocytes induces mitochondrial capacity downstream of glycolytic activation. Consistent with elevated ECAR, both *GLS* silencing and CB-839 treatment resulted in increased lactate levels (Fig. 4h), which in turn has been linked to adipocyte browning via (1) signalling through the hydroxycarboxylic acid receptor 1 (also known as G protein-coupled receptor 81, GPR81), (2) altering the redox state (NAD<sup>+</sup>/NADH ratio) and/or (3) activating the mitogen-activated protein kinase (MAPK) p38 (refs. 25–28). To dissect between these potential regulatory steps, we first incubated adipocytes with a GPR81 agonist but found no changes in OCR and ETC protein levels (Extended Data Fig. 6e,f). Furthermore, we found that NAD<sup>+</sup>/NADH levels were unaltered in siGLS versus siC adipocytes (Extended Data Fig. 6g). However, we observed that the phosphorylation of p38 MAPK, as well as its downstream targets cyclic AMP-responsive element binding protein (CREB) and activating transcription factor 2 (ATF2) were increased following *GLS* depletion and GLS inhibition (Fig. 4i,j). Similar effects on p38/CREB/ATF2 phosphorylation and increases in ETC proteins and OCR were observed following lactate incubations (Extended Data Fig. 6h,i). The dependency on p38 MAPK was tested by pretreatment with an inhibitor of this kinase (SB203580). In this experimental setup, the effects of lactate and siGLS on ETC proteins were abrogated (Fig. 4k,l).

Altogether, our data suggest that glutaminolysis coordinates glycolysis and mitochondrial capacity via HIF1 $\alpha$ , lactate and p38 MAPK (Fig. 4m).

### GLS inhibition results in weight loss and WAT browning

We next assessed whether glutamine metabolism is dysregulated by obesity also in mice. For this, we obtained adipose tissue samples from male and female mice fed chow or high-fat diet (HFD). In two WAT depots, we found that *GLS* mRNA levels were increased while *Glut1* levels were decreased following 15 weeks of HFD (Extended Data Fig. 7a). Concomitantly, we observed a reduction in glutamine-to-glutamate ratios in plasma and WAT (Extended Data Fig. 7b). As these results recapitulated and extended our findings in human WAT, we tested whether GLS inhibition in mice influenced WAT mass and carbohydrate metabolism via WAT browning. For this, mice were fed HFD for 7 weeks where the last 19 days included daily gavage administration of either CB-839 or vehicle. As shown in Fig. 5a,b, CB-839 treatment resulted in total body and fat mass loss in both male and female mice. qPCR analyses revealed an increase in the expression of *Ucp1* in inguinal WAT (iWAT) (Fig. 5c). In addition, this short-term treatment resulted in reduced circulating insulin levels and decreased HOMA-IR (Fig. 5d). As the observed effects could be due to increased systemic glutamine availability, we treated HFD-fed mice with intraperitoneal glutamine injections for 2 weeks and measured the expression of genes encoding factors involved in browning and bioenergetic pathways in iWAT. In this setup, glutamine did not affect the expression of any of the measured genes (Extended Data Fig. 7c), suggesting that the effects observed on GLS inhibition are not secondary to systemic glutamine build-up.



**Fig. 6 | Adipocyte *Gls* depletion promotes a browning phenotype in inguinal WAT.** **a**, *Gls* mRNA expression in adipose depots and different organs from *Gls*<sup>fl/fl</sup> ( $n = 8$  for adipose tissues (iWAT, eWAT and BAT) and  $n = 5$  for other organs) and *Gls*<sup>AdipoqCre</sup> ( $n = 5$ ) mice. **b**, *Gls* mRNA expression in intact WAT, mature adipocytes (MA) and the stromal vascular fraction (SVF) in the two genotypes ( $n = 3$  per condition). **c**, *Gls* protein expression in mature adipocytes isolated from iWAT of *Gls*<sup>fl/fl</sup> and *Gls*<sup>AdipoqCre</sup> mice (two mice per condition). **d**, *Gls* activity in iWAT and eWAT of *Gls*<sup>fl/fl</sup> and *Gls*<sup>AdipoqCre</sup> mice ( $n = 3$  per condition). **e**, Data from mice in a displaying the levels of glutamine (gln), glutamate (glu) and the glutamine-to-glutamate ratio in iWAT of *Gls*<sup>fl/fl</sup> ( $n = 8$ ) and *Gls*<sup>AdipoqCre</sup> ( $n = 5$ ) mice. **f**, Body weight of *Gls*<sup>fl/fl</sup> ( $n = 8$ ) and *Gls*<sup>AdipoqCre</sup> ( $n = 5$ ) mice. **g**, Fat and lean body mass determined by magnetic resonance imaging (MRI) in *Gls*<sup>fl/fl</sup> ( $n = 8$ ) and *Gls*<sup>AdipoqCre</sup>

( $n = 5$ ) mice. **h**, Weight of iWAT and eWAT of *Gls*<sup>fl/fl</sup> ( $n = 8$ ) and *Gls*<sup>AdipoqCre</sup> ( $n = 5$ ) mice. **i**, Fat cell size of iWAT and eWAT (five mice per condition) measured as described in the Methods. Boxplots display the median and the  $1.5 \times$  IQR method is used to determine the length of the whiskers. **j**, Representative haematoxylin and eosin staining of iWAT and eWAT with a specified area magnified (to the right of each image). Scale bars represent  $100 \mu\text{m}$  for the images and  $20 \mu\text{m}$  in the magnified areas. **k**, Representative haematoxylin and eosin staining of BAT with a determined area magnified (to the right side of the images). Scale bars same as in **j**. **a**, **b** and **d**–**h** show mean  $\pm$  s.e.m. Data in **a**, **b** and **d**–**i** were compared using Student's *t*-test. Relevant *P* values are shown. eWAT, epigonadal WAT; iWAT, inguinal WAT; Rel., relative.


### Adipocyte *Gls* deletion alters WAT mass and fat cell morphology

To test the effect of adipocyte *Gls* depletion in vivo, we generated adipocyte-specific *Gls* knockout mice (*Gls*<sup>AdipoqCre</sup>) by crossing *Gls*-floxed and *adiponectin*-Cre transgenic mice. In male mice, we confirmed that *Gls* expression was selectively reduced in WAT and BAT but not in the other investigated organs (Fig. 6a). Within WAT, the depletion of *Gls* was evident in the mature white adipocyte fraction, but not in the stromal cells (Fig. 6b), and resulted in reduced *Gls* protein levels and *Gls* activity as well as increased plasma glutamine-to-glutamate ratio compared with Cre-negative littermates (*Gls*<sup>fl/fl</sup>) (Fig. 6c–e). In contrast to these data, we were not able to deplete *Gls* in mature adipocytes from female mice despite clear mRNA expression of Cre recombinase (Extended Data Fig. 7d). Further studies were therefore performed only in male mice. In these animals, we found that the two genotypes exhibited similar total and lean body weights (Fig. 6f,g). The knockout mice, however, displayed a reduction in fat mass, where both the inguinal and epididymal adipose depots were reduced and contained smaller

fat cells (Fig. 6h,i). Our histological assessments also revealed a larger proportion of inguinal adipocytes with multilocular lipid droplets in *Gls* knockout mice (Fig. 6j), while there were no discernible differences in the morphology of the BAT comparing genotypes (Fig. 6k).

### *Gls* deletion promotes energy expenditure and metabolic health

As a hallmark feature of beige adipocytes is lipid droplet multilocularity<sup>29</sup>, we next investigated the cellular composition of iWAT using single-nucleus RNA sequencing. We found four major cell classes, that is, adipocytes, leukocytes, vascular cells and fibroblasts and adipogenic progenitors, where *Gls* was selectively depleted in the adipocyte fraction of *Gls*<sup>AdipoqCre</sup> mice (Fig. 7a). Through targeted examinations of the fat cells, three distinct subtypes were identified: white, beige and a minority of metallothionein-expressing adipocytes. Notably, the population of the beige subtype was substantially augmented in *Gls*<sup>AdipoqCre</sup> mice (Fig. 7b–d). Similar analyses in BAT revealed no obvious genotype-related differences in the cellular composition between




**Fig. 7 | Subclustering of mouse adipocytes identifies a distinct beige subpopulation within the iWAT of  $Gls^{AdipoqCre}$  mice. a**,  $Gls$  gene expression for each cell population in the single-nucleus RNA sequencing dataset from inguinal WAT (iWAT) of  $Gls^{fl/fl}$  and  $Gls^{AdipoqCre}$  mice ( $n = 5$  for each genotype). **b**, UMAP projection of adipocytes in iWAT of  $Gls^{fl/fl}$  and  $Gls^{AdipoqCre}$  mice. **c**, Proportion of adipocyte subpopulations in iWAT of  $Gls^{fl/fl}$  and  $Gls^{AdipoqCre}$  mice. **d**, Top marker genes across the three identifiable subpopulations in iWAT presented in a dot plot where circle sizes and colours are proportional to the detection rate and expression of the marker genes, respectively. **e**,  $Gls$  gene expression for each cell population in the single-nucleus RNA sequencing dataset from BAT of  $Gls^{fl/fl}$

and  $Gls^{AdipoqCre}$  mice. **f**, UMAP projection of adipocytes in BAT. **g**, Proportion of adipocyte subpopulations in BAT of  $Gls^{fl/fl}$  and  $Gls^{AdipoqCre}$  mice. **h**,  $Ucp1$ ,  $Slc25a42$  and  $Cfd$  mRNA expression of brown adipocyte and inguinal white adipocyte of  $Gls^{fl/fl}$  and  $Gls^{AdipoqCre}$  mice. **i**, Representative microphotographs of iWAT displaying immunofluorescence signal of TOM20, COX4 and UCPI protein in  $Gls^{fl/fl}$  and  $Gls^{AdipoqCre}$  mice. Hoechst was used to stain nuclei. Scale bars, 50  $\mu$ m. COX4, cytochrome C oxidase subunit; Cfd, complement factor D; Mt, metallothionein 1A; Slc25a42, solute carrier family 25 member 42; TOM20, translocase of outer mitochondrial membrane 20; UMAP, uniform manifold approximation and projection.

genotypes (Fig. 7e–h). To extend these results, we performed iWAT immunostainings with antibodies directed against multiple mitochondrial proteins. Our data showed that immunofluorescence signals for UCPI, COX4 and TOM20 were higher in iWAT from  $Gls^{AdipoqCre}$  versus control mice (Fig. 7i). Thus, our findings suggest that adipocyte-specific depletion of  $Gls$  results in iWAT browning with concomitant reductions in body fat.

To assess whether the observed tissue browning resulted in lactate build-up and p38 MAPK activation, we measured these parameters in

iWAT. In analogy with our data on human fat cells, we found that samples from  $Gls$  KO mice displayed higher lactate levels and p38 MAPK phosphorylation compared to control littermates (Fig. 8a,b). Moreover, several HIF1 $\alpha$  target genes were upregulated in iWAT of  $Gls$  KO mice (Extended Data Fig. 7e). We next determined whether this translates into altered metabolic phenotypes by performing high-resolution respirometry at the tissue level, whole-body indirect calorimetry and glucose tolerance tests. Our analyses revealed that iWAT from  $Gls^{AdipoqCre}$  mice displayed higher oxygen consumption than the corresponding



**Fig. 8 | Loss of *GLS* in adipose tissue promotes mitochondrial activity and protects mice against obesity.** **a**, Lactate levels in inguinal WAT (iWAT) from *Gls*<sup>fl/fl</sup> ( $n = 8$ ) and *Gls*<sup>AdipoqCre</sup> ( $n = 5$ ) mice on a chow diet. **b**, UCP1, ETC, total and phosphorylated p38 MAPK protein levels in iWAT from *Gls*<sup>fl/fl</sup> and *Gls*<sup>AdipoqCre</sup> mice fed chow diet. Proteins from the same samples were loaded on three different gels. **c**, High-resolution respirometry showing  $O_2$  consumption in iWAT (left) and BAT (right) from *Gls*<sup>fl/fl</sup> and *Gls*<sup>AdipoqCre</sup> mice fed chow diet. Data ( $n = 5$  for iWAT and  $n = 3$  for BAT in *Gls*<sup>fl/fl</sup>, and  $n = 5$  for iWAT and  $n = 4$  for BAT in *Gls*<sup>AdipoqCre</sup>) were compared using two-way ANOVA. **d**, Energy expenditure (EE) in *Gls*<sup>fl/fl</sup> ( $n = 8$ ) and *Gls*<sup>AdipoqCre</sup> ( $n = 5$ ) mice fed chow diet measured in metabolic cages. Data were analysed by two-way ANOVA (mixed-effects analysis). **e**, Data from intraperitoneal glucose tolerance test in *Gls*<sup>fl/fl</sup> ( $n = 8$ ) and *Gls*<sup>AdipoqCre</sup> ( $n = 5$ ) mice fed chow diet. The area under the curve (AUC) is displayed in the right-hand panel. **f**, Glutamine-to-glutamate ratio in iWAT (left) and plasma (right) from *Gls*<sup>fl/fl</sup> ( $n = 4$ ) and *Gls*<sup>AdipoqCre</sup> ( $n = 8$ ) mice following 8 weeks of HFD. Data were

compared using Mann–Whitney test for the left panel and Student's *t*-test for the right panel. **g**, Lactate levels in iWAT from *Gls*<sup>fl/fl</sup> ( $n = 4$ ) and *Gls*<sup>AdipoqCre</sup> ( $n = 8$ ) mice fed HFD. **h**, Energy expenditure in *Gls*<sup>fl/fl</sup> ( $n = 4$ ) and *Gls*<sup>AdipoqCre</sup> ( $n = 8$ ) mice fed HFD. Data were analysed by two-way ANOVA (mixed-effects analysis). **i**, UCP1 and ETC protein levels in iWAT from *Gls*<sup>fl/fl</sup> and *Gls*<sup>AdipoqCre</sup> mice fed HFD (four mice per condition). **j**, Representative microphotographs of UCP1 immunofluorescence in iWAT from *Gls*<sup>fl/fl</sup> and *Gls*<sup>AdipoqCre</sup> mice fed HFD. Hoechst was used to stain nuclei. Scale bar, 50  $\mu\text{m}$ . **k**, Body weight and fat mass determined by magnetic resonance imaging in *Gls*<sup>fl/fl</sup> ( $n = 4$ ) and *Gls*<sup>AdipoqCre</sup> ( $n = 8$ ) mice before and after HFD. Data were analysed by two-way ANOVA and Bonferroni's post hoc test. **l**, Data from intraperitoneal glucose tolerance test in *Gls*<sup>fl/fl</sup> ( $n = 4$ ) and *Gls*<sup>AdipoqCre</sup> ( $n = 7$ ) mice after 7 weeks of HFD. The AUC is displayed in the right panel. Data in **a**, **c–h** and **k–l** show mean  $\pm$  s.e.m. Data in **a**, **e**, **g** and **l** were compared using Student's *t*-test. Relevant *P* values are shown.

tissues from control littermates (Fig. 8c). This contrasted with our measures in BAT where there were no genotype-related differences (Fig. 8c). By placing the mice in metabolic cages, we confirmed higher energy expenditure in *Gls*<sup>AdipoqCre</sup> versus control mice without any changes in food intake or locomotor activity (Fig. 8d and Extended Data Fig. 7f). These differences were associated with improved glucose tolerance in *Gls* KO mice (Fig. 8e). Following HFD feeding, the increases in glutamine-to-glutamate ratio and lactate levels, elevated energy expenditure as well as iWAT browning were retained in *Gls*<sup>AdipoqCre</sup> mice (Fig. 8f–j), which in turn protected them from HFD-induced fat mass accumulation and glucose intolerance (Fig. 8k,l). Altogether,

our studies in mice corroborate our human data and indicate that glutamine-to-glutamate conversion via GLS in white adipocytes regulates energy expenditure and metabolic health.

## Discussion

Herein, we demonstrate that obesity-induced insulin resistance is characterized by increased fat cell glutaminolysis, which is evident at the transcript, protein and metabolite levels in both humans and mice. In human white adipocytes, *GLS* transcription is induced by TNF and a targeted reduction in *GLS* activity results in a robust induction of metabolic and thermogenic transcriptional programs with increases in

glycolysis, lactate levels and mitochondrial respiration. We find that this WAT browning phenotype is dependent on p38 MAPK signalling, and is phenocopied in inguinal, but not epigonadal or brown adipose regions of male mice with adipocyte-specific GLS depletion. Consequently, these mice display increased energy expenditure and are protected against HFD-induced fat mass accumulation and glucose intolerance. Altogether, our results uncover a role for adipocyte glutamine turnover in regulating white adipocyte energy consumption and whole-body metabolic health.

A previous study has proposed that glutamine is a substantial mitochondrial energy source in white adipocytes from rats<sup>30</sup>. Our data indicate that this also pertains to human and mouse fat cells where inhibition of glutaminolysis results in increased use of glucose. This metabolic adaptation promotes oxidative capacity and a thermogenic phenotype via activation of the p38 MAPK pathway in both human adipocytes and mouse iWAT. Our results are in line with previous work in murine beige adipocytes demonstrating that p38 MAPK activation promotes *Ucp1* expression and oxidative capacity<sup>31–35</sup>. Although further studies are required to elucidate the mechanism by which glutaminolysis influences p38 MAPK signalling, we propose that GLS inhibition results in a reduction of  $\alpha$ -ketoglutarate and thereby elevated HIF1 $\alpha$  levels. The ensuing HIF1 $\alpha$ -mediated increase in glycolysis exceeds the oxidative capacity of the cell, resulting in lactate build-up and activation of thermogenic transcriptional programs via p38 MAPK signalling. While this model is based on metabolite add-backs and withdrawals (glucose, pyruvate, lactate, glutamine and  $\alpha$ -ketoglutarate), pharmacological inhibitors (BPTES, CB-839, SB203580, Inhibitor VI and UK5099), genetic depletion (siGLS and *Gls*<sup>AdipoqCre</sup>) and gain-of-function experiments (*GLS* over expression), we acknowledge that each step may be interconnected and that the pathway may therefore be more complex than described herein. For example, while we did not observe any changes in NAD<sup>+</sup>/NADH in *GLS*-depleted cells, these assessments were performed in whole cell lysates after several days of *GLS* knockdown. It is possible that dynamic changes in the redox state (potentially in different organelles) may be important in promoting the browning effect as has been reported previously<sup>25,36</sup>. Furthermore, lactate has recently raised considerable interest where multiple effects have been attributed to this metabolite<sup>37</sup>, including actions independent of its metabolism<sup>38</sup>. Thus, further studies are needed to understand the interactions between glutamine metabolism, lactate turnover and thermogenic activation.

Comparisons of control and *Gls*<sup>AdipoqCre</sup> mice using histological and single-nucleus RNA sequencing profiling of iWAT, revealed a substantial increase in the proportion of beige multilocular fat cells, marked by the expression of *Pparg1a*, *Cidea* and *Acaca*, in the knockout mice. Functionally, these results were corroborated by high-resolution respirometry demonstrating higher oxygen consumption in iWAT of *Gls*<sup>AdipoqCre</sup> mice compared with Cre-negative littermates. By contrast, no changes in BAT cellularity or tissue respiration were observed comparing genotypes. In mice, the inguinal depot is highly susceptible to undergo browning<sup>29,39</sup>, and our data align with previous reports demonstrating that induction of a brown-like phenotype selectively in iWAT improves metabolic health<sup>40,41</sup>. The mice included in the present study were housed at room temperature. It is possible that exposure to cold or thermoneutrality could affect the observed phenotype as these conditions have pronounced effects on glutamine turnover in BAT<sup>42,43</sup>.

Our analyses of human and mouse WAT in obesity revealed that *GLS* mRNA levels were increased in both sexes compared with relevant control groups. We therefore set out to generate adipocyte-specific *Gls* knockout mice. However, although Cre recombinase was expressed in mature fat cells of female *Gls*<sup>AdipoqCre</sup> mice, we observed no reduction of *Gls* expression. Thus, while our conclusions in humans and wild-type mice are relevant for both sexes, the present knockout model data only pertains to male animals. Although sex-specific differences in the Cre-loxP system have been described<sup>44,45</sup>, we cannot currently explain the mechanisms underlying the poor gene editing efficiency in female

mice. However, administration of CB-839 had similar effects in both sexes, indicating that there are no qualitative differences in the role of glutamine turnover between females and males.

We provide evidence that increased white adipocyte glutaminolysis is linked to a reduction in the glutamine-to-glutamate ratio in both WAT and plasma. Conversely, we find that an adipocyte-specific depletion of GLS in male mice results in increased circulating glutamine versus glutamate levels. Together with data from healthy human participants<sup>11</sup> and rats<sup>46</sup>, this indicates that WAT contributes to plasma glutamine-to-glutamate stoichiometry and that this ratio partly reflects WAT function. Similar effects have been reported in non-alcoholic steatohepatitis where hepatic *GLS* expression is increased, the plasma glutamine-to-glutamate ratio is decreased and enzyme inhibition reduces the hepatocyte lipid content<sup>47</sup>. Thus, inhibition of glutaminolysis may be a potential therapeutic target to improve energy homeostasis in people living with obesity, type 2 diabetes and/or steatohepatitis. As we found here that a short-term treatment with CB-839 in HFD-fed mice resulted in weight loss and iWAT browning, randomized controlled trials testing the efficacy of GLS inhibitors such as CB-839 in improving metabolic health would be interesting to explore. In clinical studies, these compounds have been shown to be safe and they are currently being studied as anticancer drugs<sup>48</sup>.

In conclusion, our results highlight that glutamine metabolism in white adipocytes is an important determinant of energy consumption and metabolic health. We base this on multiple model systems where reductions in GLS activity specifically in fat cells, induces a transcriptional response that rewires glucose oxidation and increases mitochondrial respiratory capacity. The resulting increase in energy expenditure protects against HFD-induced glucose intolerance in mice and correlates with a beneficial clinical profile in humans.

## Methods

### Clinical studies

**Anthropometric and metabolic examinations.** All examinations were conducted in the morning after an overnight fast. Anthropometric measures were determined; obesity was defined as body mass index (BMI)  $\geq 30$  kg m<sup>-2</sup>, and waist and hip circumferences were used to calculate waist-to-hip ratio. Body fat percentage was determined by bioimpedance (Bodystat). Energy expenditure was measured by indirect calorimetry using an open-system ventilated hood (Deltatrac II; Datex-Ohmeda). Blood samples were obtained to measure circulating levels of leptin and insulin. Homeostasis Model Assessment of insulin resistance (HOMA-IR) was calculated as (fp-glucose in mmol l<sup>-1</sup>  $\times$  fS-insulin in mU l<sup>-1</sup>)/22.5 (ref. 49). Participants in cohort 1 (which includes people living with obesity scheduled for bariatric surgery and non-obese controls, NCT01727245) underwent a hyperinsulinaemic euglycemic clamp as described<sup>50</sup>. The mean glucose infusion rate (glucose disposal) between 60 and 120 min was determined (*M* value is mg of glucose uptake per kg of body weight per min) and was expressed corrected for mean plasma insulin during steady state (*M/I*). Clinical data for cohorts 1 and 2 are presented in Supplementary Table 1.

**Investigations of WAT biopsies.** Subcutaneous WAT needle biopsies were obtained under local anaesthesia from the periumbilical area<sup>51</sup>. These isolated fat cells were prepared by collagenase digestion<sup>52</sup>. Mean fat cell volume was determined and lipogenesis experiments were performed as described<sup>53</sup>. For the latter, the medium was supplemented with a low concentration of unlabelled and tritiated glucose and insulin-stimulated incorporation of <sup>3</sup>H into total lipids was determined. Results were expressed as amount of glucose incorporated into lipids (nmol glucose 2 h<sup>-1</sup> (10<sup>7</sup> fat cells)<sup>-1</sup>).

**Omics in clinical samples.** Plasma and WAT metabolomics data from cohort 1 and WAT transcriptomic data from cohort 3 were generated and presented in ref. 7, ref. 54 and ref. 15, respectively. Targeted gene

expression analyses in men and women were performed in previously published data from ref. 14. For correlations between metabolites, gene expression and clinical parameters, the Hmisc package (rcorr function) in R Studio (v.4.2.1) was used.

**Ethical approvals.** All studies were approved by the regional ethics boards in Stockholm (cohort 1 and 3) and Paris (cohort 2), and informed written consent was obtained from all study participants.

### Mouse studies

For all animal studies, mice were handled following the European Union laws and guidelines for animal care, health inventories were performed according to the guidelines of the Federation of European Laboratory Animal Science Associations and special care was taken to minimize animal suffering and to reduce the number of mice used.

**HFD intervention in wild-type mice.** Male C57BL/6J mice, sourced from Charles River Laboratories (France) at 7 weeks of age, were group-housed under a 12-h light-dark cycle with ad libitum access to food and water. Following 1 week of acclimatization, the mice were assigned to either a standard chow diet or a HFD for an additional 15 weeks. For the CB-839 study, C57BL/6J male mice from Envigo (France) were acclimatized to a standard chow diet for 2 weeks. Housed in groups of five, they were subjected to a 12-h light/12-h dark cycle with ad libitum access to food and water. On reaching 10 weeks of age, mice were switched to either a standard chow diet or an HFD for 5 weeks. After 3 weeks on the HFD, mice were randomly allocated to treatment groups on the basis of body weight. Those on the HFD received daily gavage administration of CB-839 (200 mg kg<sup>-1</sup> body weight) or vehicle for 19 days (25% (w/v) hydroxypropyl- $\beta$ -cyclodextrin (ThermoFisher) in 10 mmol l<sup>-1</sup> citrate buffer (pH 2)), while the standard chow group received vehicle only. Blood glucose and plasma insulin levels were monitored 12 days posttreatment initiation. After 19 days, mice were euthanized and tissue weights were recorded. Samples were snap-frozen in liquid nitrogen. All mice were housed in the animal facility of Pitié-Salpêtrière, in conformity with EU regulations, and studied according to a protocol that received ethics approval from the French ministry for research.

**Generation, interventions and phenotyping of *Gls*<sup>Adipoq-Cre</sup> mice.** Adiponectin-Cre mice were bred with *Gls*<sup>fl/fl</sup> mice (*Gls*<sup>tm2.1Sgray/J</sup>), stock 017894) to generate adipocyte-specific *Gls*-depleted mice (*Gls*<sup>AdipoqCre</sup>). *Gls*<sup>fl/fl</sup> littermates were used as controls. Mice were housed in groups at the KM-B animal facility in ventilated cages (with a 12-h light/12-h dark cycle (lights between 6:00 and 18:00) in a temperature-controlled (20–24 °C, 50% humidity) facility with ad libitum access to food and water. All experimental procedures were approved by the Stockholm North Animal Ethical Committee. Five to seven-week-old male mice were fed with an HFD (D12492i, 60% kcal fat, Research Diets) for a duration of 7 weeks. Five weeks after the start of the HFD, mice were fasted for 4 h and glucose tolerance was assessed by an intraperitoneal glucose injection (1.5 g kg<sup>-1</sup>). Blood glucose concentration was monitored from the tail tip using a glucometer (Contour XT, Bayer) before and at the indicated time intervals following glucose injection. Indirect calorimetry was performed 1 week later in the Phenomaster Home cage system (TSE Systems). Ambulatory and locomotor activity was automatically assessed by counting the number of photo beam breaks in the *x* and *y* axis. A feeding sensor monitored food intake without disturbances by the experimenters. Lean and fat mass were measured before the start of the HFD and the indirect calorimetry protocols using the EchoMRI-100 (EchoMRI). Seven weeks after the start of the HFD protocol, at 13–15 weeks of age, mice were euthanized under general anaesthesia by avertin injection, and the wet weight of each dissected tissue was measured. Subsequently, one part of the samples was snap-frozen in liquid nitrogen and one part was fixed in in

4% paraformaldehyde (PFA). The same procedures were conducted in another cohort of mice kept on a standard chow diet (CRM (P), 801722, Special Diets Services). Chow mice were individually housed in metabolic cages at 14–18 weeks of age and dissected 4 weeks later.

**Plasma, media and tissue analyses of glutamine, glutamate and lactate.** The glutamine-to-glutamate ratio in plasma, media and in iWAT was measured using the Glutamine/Glutamate-Glo Assay (Promega). Lactate measurements in snap-frozen iWAT samples were performed at The Swedish Metabolic Center (detailed in the targeted metabolic analysis below). Data were normalized by tissue weight.

**Immunofluorescence analyses in murine WAT.** As described in ref. 54, WAT samples were fixed in 4% PFA for 1 day, embedded in paraffin, cut into 5- $\mu$ m sections and stained with hematoxylin and eosin (Sigma-Aldrich). For immunostaining, sections were rehydrated by successive baths in xylene, ethanol and PBS followed by blocking with 10% goat serum. The tissue sections were subsequently incubated overnight with antibodies directed against UCPI (1:100), COX4 (1:100) and TOM20 (1:100). Goat anti-Rabbit Rhodamine Red-X (1:500) was used as a secondary antibody and Hoechst 34580 (1:500) was applied for 20 min to counterstain nuclei. Images were acquired using a Axio Observer Z1 inverted fluorescence microscope (Zeiss) and the AxioVision software.

### Determination of fat cell size by image analysis

Qupath (v.0.3.4)<sup>55</sup> was used to export histology images (tiles 2,048  $\times$  2,048 pixels in .tiff format, 5 $\times$  downsample). Fiji<sup>56</sup> with the Adiposoft<sup>57</sup> plugin (v.1.16) was used to quantify adipocyte size of whole tissue sections, pixel size was set to 1.2  $\mu$ m, with expected diameter of 5–150  $\mu$ m. An unpaired Student's *t*-test was performed in R v.4.2.3 (R Core Team, v.2021) using the rstatix package.

### Single-nucleus RNA sequencing

**Nuclei isolation and library preparation.** BATs and WATs were collected from chow diet-fed *Gls*<sup>fl/fl</sup> mice and *Gls*<sup>AdipoqCre</sup> mice (*n* = 5 for each genotype) and promptly frozen in liquid nitrogen. Samples from each depot and genotype were pooled for nuclei isolation. Briefly, frozen tissue samples were minced and homogenized in cold lysis buffer using a gentleMACS Dissociator (Miltenyi Biotec). After addition of lysis buffer with Triton X-100 (X100, Sigma-Aldrich), the lysates were filtered and washed before centrifugation to collect the nuclei pellet. The isolated nuclei were stained with DAPI (D9542, Sigma-Aldrich), sorted, and counted before loading onto a 10X Chip G (10X Genomics). Libraries were prepared using the Chromium Single-Cell v.3.1 kit and sequenced on a Nextseq 2000 platform (Illumina).

**Single-nucleus RNA sequencing data preprocessing.** Raw sequencing files were processed using Cell Ranger v.7.0.1 based on the default parameters to demultiplex cell barcodes and generate cell-by-gene expression matrices. The mm10 mouse genome (refdata-gex-mm10-2020-A) from 10X genomics was used. We next applied SoupX v.1.6.2 (ref. 58) and DoubletFinder v.2.0.3 (ref. 59) to remove ambient RNA contamination and doublets, respectively. We filtered cells with more than 5% of mitochondrial RNA and excluded haemoglobin and mitochondrial genes, ribosomal protein families, *MTRNR* and *MALAT1* for downstream analyses.

**Integration and cell type identification.** We integrated the libraries on experimental conditions to remove batch effects using scVI v.0.16.2 (ref. 60). Briefly, all matrices were merged by Seurat v.4.1.3 (ref. 61), and a subset of the top 2,000 highly variable features was identified. From scVI, get\_latent\_representation was used for generating the latent embedding. By leveraging this latent embedding, we built a shared nearest neighbour graph, clustered cells and visualized all cells in a two-dimensional embedding by using Seurat's FindNeighbors,

FindClusters and RunUMAP. FindMarker was used for determination of differentially expressed genes. We annotated clusters through comparison of highly expressed genes of each cluster with well-established adipose cell type specific markers<sup>62,63</sup>.

### High-resolution respirometry in adipose tissues

**Dissection and preparation of iWAT pieces.** Inguinal WAT mitochondrial respiration was measured *ex vivo* using high-resolution respirometry following previously established methods (Oxygraph 2k, Oroboros)<sup>64</sup>. From *GLS<sup>fl/fl</sup>* and *GLS<sup>AdipoqCre</sup>* mice, iWAT was dissected, cleaned and cut in approximately 20 mg pieces. In total, 40 to 55 mg of the tissue was placed in 2 ml of ice-cold BIOPS buffer (2.77 mmol l<sup>-1</sup> CaK<sub>2</sub>EGTA anhydrous, 7.23 mmol l<sup>-1</sup> K<sub>2</sub>EGTA anhydrous, 5.77 mmol l<sup>-1</sup> Na<sub>2</sub>ATP, 6.56 mmol l<sup>-1</sup> MgCl<sub>2</sub>·6H<sub>2</sub>O, 20 mmol l<sup>-1</sup> Taurine, 15 mmol l<sup>-1</sup> Na<sub>2</sub> phosphocreatine, 20 mmol l<sup>-1</sup> Imidazole, 0.5 mmol l<sup>-1</sup> eithiothreitol, 50 mmol l<sup>-1</sup> MES) until the start of the assay. Excess of BIOPS buffer was then removed by blotting the tissue on filter paper before placing the samples in a respirometry chamber containing 2.1 ml of MRO5 buffer (0.5 mmol l<sup>-1</sup> EGTA, 3 mmol l<sup>-1</sup> MgCl<sub>2</sub>·6H<sub>2</sub>O, 60 mmol l<sup>-1</sup> lactobionic acid, 20 mmol l<sup>-1</sup> taurine, 10 mmol l<sup>-1</sup> KH<sub>2</sub>PO<sub>4</sub>, 20 mmol l<sup>-1</sup> HEPES, 110 mmol l<sup>-1</sup> D-sucrose, 1 g l<sup>-1</sup> fatty acid free bovine serum albumin).

**High-resolution respirometry for inguinal white adipose.** After adding the tissue into the respiration chamber, the chamber was closed and allowed to equilibrate before adding any substrates. Leak respiration associated with complex I was assessed by adding 2 mmol l<sup>-1</sup> malate, 10 mmol l<sup>-1</sup> pyruvate and 10 mmol l<sup>-1</sup> glutamate. After O<sub>2</sub> consumption rates were stabilized, ADP was added to a final concentration of 5 mmol l<sup>-1</sup>, triggering complex I-driven coupled respiration. After stabilization, complex II respiration was stimulated by adding 10 mmol l<sup>-1</sup> succinate, obtaining the respiration rate corresponding to complex I + complex II-driven respiration. The maximal capacity of the electron transfer system (ETS) was assessed by titrating carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone in 0.5 μmol l<sup>-1</sup> steps. Complex II-linked ETS capacity was evaluated by inhibiting complex I respiration with 0.5 μmol l<sup>-1</sup> rotenone. Finally, 2.5 μmol l<sup>-1</sup> antimycin A was added into the chamber, inhibiting complex III and therefore blocking mitochondrial electron circulation. The subsequent residual oxygen consumption—corresponding to non-mitochondrial respiration—was subtracted from the previous measured states. O<sub>2</sub> consumption was normalized to the amount of tissue mass added in each assay. Mitochondrial membrane integrity and damage was assessed by adding cytochrome C after measuring complex I respiration. In our measurements, we did not observe differences in O<sub>2</sub> consumption following this control step.

**Dissection and preparation of BAT pieces.** Interscapular BAT was dissected and separated from the surrounding white fat. Approximately 20 mg of the tissue was placed in a microcentrifuge tube containing 200 μl of MRO5 buffer and gently homogenized with a handheld pestle homogenizer. Then 20 μl (roughly 2 mg) of homogenate was added to the respiratory chamber containing 2.1 ml of MRO5 buffer.

**High-resolution respirometry protocol for BAT.** Uncoupled complex I- and complex I + complex II-driven mitochondrial respiration and maximal ETS capacity were evaluated by following the protocol described above for iWAT, minus the addition of ADP into the respirometry chamber.

### Cell studies

**Differentiation and perturbations of human adipocytes.** Isolation, proliferation and differentiation of human adipocyte progenitor cells (from an anonymous male donor, ethical permit no. 2009/764-32, regional ethics board of Stockholm) were performed as described<sup>7</sup>. Short interfering oligonucleotides (siRNAs) were transfected by

electroporation using a Neon Transfection System (1,300 V, 20 ms, two pulses) using the 100 μl of Kit (Invitrogen) at day eight of adipocyte differentiation. All transfections were performed using a final concentration of 20 nmol l<sup>-1</sup> siRNA oligonucleotides. Results were compared with non-silencing control siRNAs. A full list of RNA interference (RNAi) oligonucleotides is provided in Supplementary Table 2. In addition to the inhibitors used in the Seahorse assays, the cells were treated with the following chemicals (final concentrations and incubation times): dimethylsulfoxide (DMSO), BPTES (10 μmol l<sup>-1</sup> for 3 h), CB-839 (10 μmol l<sup>-1</sup> for 6 h), eta-ketoglutarate (2 mmol l<sup>-1</sup> for 1 day), GPR81 agonist (500 nmol l<sup>-1</sup> for 1 day), insulin (50 nmol l<sup>-1</sup> for 15 min or 4 h), rapamycin (50 nm l<sup>-1</sup> for 4 h), TNF (2 ng ml<sup>-1</sup> for 4 h), STAT3 inhibitor VII (5 μmol l<sup>-1</sup> for 5 h), NF-κB inhibitor (trifluoroacetate, 50 μg ml<sup>-1</sup> for 5 h), JNK inhibitor SP600125 (10 μmol l<sup>-1</sup> for 5 h), isoprenaline (10 μmol l<sup>-1</sup> for 6 h), SB203580 (10 μmol l<sup>-1</sup> for 24 h in RNAi experiments and a total of 3 h in lactate treatments including 2.5 h of preincubation), 2-deoxyglucose (100 μmol l<sup>-1</sup> for 4 h), UK5099 (10 μmol l<sup>-1</sup> for 4 h), pyruvate (5 mmol l<sup>-1</sup> for 4 h), PF-739 (5 μmol l<sup>-1</sup> for 1 day), sodium lactate (20 mmol l<sup>-1</sup> for 30 min) and HIF Inhibitor VI (100 μmol l<sup>-1</sup> for 4 h). For the glutamine depletion experiment, DMEM/F12 without glutamine was used either supplemented or not with 2.5 or 10 mmol l<sup>-1</sup> of glutamine. All catalogue numbers and suppliers are detailed in Supplementary Table 2.

To generate cells with doxycycline-inducible *GLS* expression, the pCW-Cas9 plasmid (Addgene, no. 50661) was digested using BamHI-HF and NheI-HF and dephosphorylated using Calf Intestinal Alkaline Phosphatase according to the instructions from New England Biolabs (NEB). The digested plasmid was gel-purified using NucleoSpin Gel and PCR Clean-Up (Macherey-Nagel) and ligated overnight at 16 °C using T4 DNA ligase (NEB) with a codon-optimized sequence of *GLS*. The insert was generated by PCR from two distinct gBlocks as the sequence complexity was too high for synthesis (primers listed in Supplementary Table 2). Stable competent cells (*E. coli*, High efficiency, NEB, cat. no. C3040H) were transformed with the ligated plasmid according to the manufacturer's instructions and single colonies were selected and cultured. From these, plasmids were extracted using QIAprep Spin Miniprep Kit (Qiagen) and verified by Sanger sequencing. Lentiviruses were created by transfecting human embryonic kidney 293 cells with this plasmid together with two additional packaging vectors (Addgene nos. 12259, 12260) using Opti-MEM and Lipofectamine 3000 (ThermoFisher) according to the manufacturer's instructions. Viruses were collected from the conditioned media 2 days following transfection and filtered using Puradisc 25-mm 0.45-μm PES syringe filters (VWR). Around 200,000 proliferating adipocyte progenitor cells per well were seeded and cultured without antibiotics, then spinfected with 50,000 ng of virus for 1 h, 800g at 37 °C. Three days later, cells were incubated with 1 ng ml<sup>-1</sup> puromycin. The selection was stopped when control cells in parallel wells were no longer viable. Induction of *GLS* was carried out by adding 2 ng ml<sup>-1</sup> doxycycline to the cell culture media for at least 1 day.

To reintroduce *GLS* in siRNA-transfected adipocytes, *GLS* mRNA was *in vitro* transcribed using a DNA template encoding a codon-optimized coding sequence of *GLS* driven by a T7 promoter according to the HiScribe T7 ARCA mRNA Kit (with tailing, NEB no. E2060S). N1-Methylpseudo-UTP (cat. no. NU-890L, Saveen Werner) was added to the reaction to increase mRNA stability and thereby extend the intracellular expression. A total of 37 pmol of *GLS* mRNA was added in each Neon transfection (1,700 V, 20 ms, one pulse) with or without *GLS* siRNA as described above. Primers used to generate the DNA template are listed in Supplementary Table 2.

**Mature adipocyte isolation and culture.** Following dissection, WAT was subjected to careful washing and fine mincing. The minced tissue was thereafter placed in vials containing a Krebs–Ringer phosphate buffer (composed of 0.9% NaCl, 0.1 M NaH<sub>2</sub>PO<sub>4</sub>, 0.11 M CaCl<sub>2</sub> and

0.154 M KCl, with a pH of 7.4) supplemented with 10% FBS, 5 mmol l<sup>-1</sup> D-glucose, 1% penicillin-streptomycin (Thermo Fisher Scientific) and 0.05% collagenase type 1 (Sigma-Aldrich). The samples were placed in a shaking water bath set at 37 °C for a duration of 45 min. Subsequently, any connective tissue or substantial undigested fragments were effectively eliminated by filtration through a 250-µm nylon mesh. The resultant floating adipocytes underwent a series of four washes using PBS supplemented with 10% FBS, 1% penicillin-streptomycin and 5 mmol l<sup>-1</sup> glucose (all from Sigma-Aldrich). The washed adipocytes were then poised for downstream analyses, either in their fresh state or following freezing at a temperature of -80 °C.

Human mature adipocytes were cultured within 6.5-mm Transwells (Costar-3413 and 3397), following a previously published protocol<sup>65</sup>. In brief, 30 µl of densely packed human adipocytes (approximately 60,000 cells) were carefully dispensed into each well. The Transwells were then inverted and positioned over a well of 24-well plates containing 1 ml of medium comprising DMEM/F12, 10% FBS and 1% penicillin-streptomycin. After a 4-h stabilization period, the cells were incubated with the following chemicals (final concentrations and incubation times): DMSO, CB-839 (10 µmol l<sup>-1</sup> for 2 days) and TNF (10 ng ml<sup>-1</sup> for 1 day).

**RNA isolation, cDNA synthesis and qPCR.** Total RNA was extracted from cells or intact human/murine WAT as described<sup>7</sup>. The RNA concentration and purity was measured using Varioskan Lux (ThermoFisher) and samples were reverse transcribed using iScript complementary DNA (cDNA) synthesis kits (BioRad). Messenger RNA levels were determined using TaqMan (Applied Biosystems) or SYBR-green (BioRad) assays and relative expression levels were calculated with the comparative Ct-method, that is,  $2^{\Delta\text{Ct-target gene}}/2^{\Delta\text{Ct-reference gene}}$ . All primers are listed in Supplementary Table 2.

**Western blot.** Western blots were performed as described previously<sup>7</sup> except that the membranes were scanned using a ChemiDoc MP system (BioRad). For experiments where the proteins of interest run at the same size, lysates were subdivided in equal amounts and loaded on separate gels as detailed in the respective figure legends. All antibodies used are listed in Supplementary Table 2.

**Immunofluorescence analyses in human adipocytes.** Cells were seeded on milli EZSlide-4 well slides and fixed in 4% PFA for 15 min at room temperature. Cells were washed twice with PBS, permeabilized using PBS supplemented with 0.2% Triton-X100 for 10 min and blocked for 30 min in PBS containing 2% bovine serum albumin (Sigma-Aldrich). The cells were subsequently incubated overnight with primary antibodies targeting UCPI (1:100) or COX4 (1:100). The antibodies were diluted in PBS supplemented with 5% normal goat serum. Cells were washed three times with PBS containing 0.05% Tween-20 and incubated with goat anti-Rabbit Rhodamine Red-X secondary antibody (1:500) for 60 min. Subsequently PBS supplemented with Hoechst 34580 (1:500) and BODIPY 493/503 (1:2,500, ThermoFisher) was applied for 15 min to counterstain nuclei and lipid droplets, respectively. Finally, cells were washed in PBS and then mounted in fluorescence mounting medium (Fluoromount Aqueous Mounting Medium, refractive index 1.4). Images were obtained using an Axio Observer.Z1 inverted fluorescence microscope (Zeiss) and the AxioVision software.

**Human adipocyte adiponectin secretion.** For analyses of conditioned media from human adipocytes, samples were collected at day 14 of differentiation. Secretion of adiponectin was determined by ELISA (R&D Systems) according to the manufacturer's instructions.

**Redox balance measurements.** Cultured siC or siGLS adipocytes were collected at day 14 of differentiation. For analyses of NAD<sup>+</sup> and NADH,

the NAD<sup>+</sup>/NADH Assay Kit (cat. no. ab65348) was used according to the manufacturer's instructions. Data were normalized by protein concentrations per sample.

**Seahorse assays and CyQUANT analyses.** Real-time measurements of oxygen consumption and ECARs were performed using a Seahorse XF96 Extracellular Flux Analyzer (Agilent Technologies) as previously described<sup>54</sup>. In brief, adipocytes were incubated in Seahorse DMEM medium (pH 7.4) supplemented with 1 mmol l<sup>-1</sup> pyruvate, 2 mmol l<sup>-1</sup> glutamine and 10 mmol l<sup>-1</sup> glucose. The assays were performed by sequential addition of 1.5 µmol l<sup>-1</sup> oligomycin (inhibitor of ATP synthesis), 1.5 µmol l<sup>-1</sup> carbonyl cyanide-p-trifluoromethoxyphenylhydrazone and 0.5 µmol l<sup>-1</sup> rotenone/antimycin A (inhibitors of complex I and complex III of the respiratory chain, respectively). To assess responses to glucose addition during glycostress tests, cells were incubated in medium with 2 mmol l<sup>-1</sup> glutamine but without glucose and pyruvate. The assays were performed by sequential addition of 10 mmol l<sup>-1</sup> glucose, 1 µmol l<sup>-1</sup> oligomycin and 50 mmol l<sup>-1</sup> 2-deoxyglucose. Mitochondrial fuel stress tests were performed using the XF96 fuel kit after acute injection of UK5099 (2 µmol l<sup>-1</sup> per well) or Etomoxir (4 µmol l<sup>-1</sup> per well). Seahorse data were normalized using the CyQUANT Kit (ThermoFisher) according to the manufacturer's instructions. Immediately after Seahorse analysis, the cells were incubated with the CyQUANT reagent and fluorescence was measured. For estimation of basal and maximal respiration, the mean non-mitochondrial respiration was subtracted from the mean values of basal and maximal respiration. For glycostress tests, the mean non-glycolytic acidification was subtracted from all data points.

**RNA sequencing and pathway analyses.** Total RNA from siC and siGLS cells was isolated as described above and used for library preparation. The yield and quality of the amplified libraries were analysed using Qubit (Thermo Fisher) and TapeStation (Agilent) and subsequently normalized and combined. These pools were sequenced on the Illumina Nextseq 2000 P2 100 cycle sequencing run, generating 59 base paired end reads with dual index. Basecalling and demultiplexing was performed using CASAVA software with default settings generating Fastq files aligned to GRCh38 for further downstream mapping and analysis. Raw counts were normalized and analysed using DESeq2 in R studio (v.4.1.1). Pathway analyses were performed using GSEA (gene set enrichment analysis) and ProFAT<sup>18</sup>.

**GLS activity assay.** In human and mouse adipocytes, GLS activity was determined using the Glutaminase Assay Kit (Abcam). In brief, samples were homogenized on ice in 1 ml of assay buffer and subjected to 8,000g centrifugation for 10 min at 4 °C. Protein concentrations were determined by Pierce BCA assay (Thermo Scientific). Samples containing equal amounts of protein were incubated with kit reagents at 37 °C, and fluorescence was detected over time using a Varioskan Lux. Control samples exposed to the kit reagent mixture lacking GLS substrate were used to measure endogenous basal glutamate levels. GLS activity was calculated on the basis of the increase in glutamate over time. Data were normalized by protein concentration for each sample.

**Targeted glutamine and glutamate measurements.** Glutamine and glutamate levels in adipocytes were determined using the Glutamine/Glutamate-Glo Assay (Promega). One half of the volume of the lysed cells was used to measure glutamate and the other half was used to measure glutamine. Protein concentrations were determined by Pierce BCA assay (Thermo Scientific) and samples were normalized to total protein content.

**Chromatin immunoprecipitation.** Chromatin immunoprecipitation against c-Jun was performed using Magna CHIP HiSense Chromatin Immunoprecipitation Kit (cat. no. 17-10460, Sigma), following the

manufacturer's instructions. The antibody targeting c-Jun (cat. no. 9165, Cell Signalling), was added at the concentration of 1:50, as suggested by the manufacturer. A negative control was generated using IgG Ab (cat. no. 7074S, Cell Signalling). Pull down enrichment quantification was performed using normal qPCR with reverse transcription as above described with the primer set in Supplementary Table 2. Relative enrichment was calculated using input enrichment ( $(\text{Ct Input} - \log_2 100) \rightarrow 100 \times 2^{(\text{Adjusted input} - \text{Ct IP})}$ ) and fold change against IgG signal (Ct IP/Ct IgG).

**Adipocyte U-<sup>13</sup>C glucose labelling.** Cells were washed twice with PBS and thereafter incubated with DMEM without glucose (cat. no. 11966025, Thermo Fisher) supplemented with an addition of 5.5 mM glucose (cat. no. G8270, Sigma) or U-<sup>13</sup>C6 D-Glucose (cat. no. 389374, Sigma) for 4 h. Cells were washed with cold PBS twice before being lysed in 90% ice-cold methanol (cat. no. 34860-1L-R, Sigma). Before cell collection, 1 ml of the media was extracted and centrifuged at 21,000g for 10 min at 4 °C then frozen. One millilitre of ice-cold 90% methanol was added to facilitate subsequent metabolic tracing analysis.

**Lactate measurements.** Lactate was measured in cell media using the Lactate-Glo Assay (Promega). Data were normalized by protein concentration per well.

**Targeted metabolite analyses.** Metabolites were profiled at the Swedish Metabolomics Centre. To trace U-<sup>13</sup>C-glutamine conversion, human adipocytes were treated with 10 μmol l<sup>-1</sup> of BPTES or vehicle (DMSO) and 2.5 mmol l<sup>-1</sup> U-<sup>13</sup>C-glutamine (Sigma-Aldrich) for 1 h. The cell, tissue and media samples were extracted with 1 ml of 90% methanol (diluted in water). Two aliquots of the extracts were analysed by (1) gas-chromatography-mass spectrometry (GC-MS) and (2) liquid chromatography-mass spectrometry (LC-MS). For GC-MS measurements, derivatization and GC-MS analysis were performed as described previously<sup>66,67</sup>. The extracted mass spectra were annotated (putatively/tentatively identified) by library comparisons of their retention index and mass spectra<sup>68</sup>. Mass spectra and retention index comparison was performed using NIST MS v.2.2 software, and annotation of mass spectra was based on reverse and forward searches. Both the Swedish Metabolomics Centre's in-house standards libraries and public libraries as NIST (<https://chemdata.nist.gov/>), MoNA (<https://mona.fiehnlab.ucdavis.edu/>) and MS-DIAL (<https://systemsomicslab.github.io/compms/msdial/main.html>) was used. Peak detection and peak area calculations of both labelled and unlabelled fragments was done as described in ref. 69

The LC-MS analysis of amino acids was conducted using ultrahigh-performance liquid chromatography with electrospray ionization and quadrupole time of flight after the amino acids were derivatized with AccQ-Tag (Waters). The derivatized amino acids were identified on the basis of their retention time and exact mass. The acquired LC-MS data were converted to XML and eventually to NetCDF format, then the peaks integration and labelling calculation were conducted as described<sup>41</sup>.

### Statistical analyses

Unless otherwise stated, results are reported as mean ± standard error of the mean (s.e.m.) with individual data points shown for experiments with fewer than ten replicates per sample group. The number of independent experiments and relevant statistical methods (all two-sided) for each panel are detailed in the corresponding figure legends. Statistical analyses were performed using Prism (v.9.2.0, GraphPad Software), JMP (v.15.1, SAS) or R v.4.1.1/4.2.1.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

Data generated or retrospectively analysed in this study are publicly available in the National Center for Biotechnology Information Gene Expression Omnibus repository under the accession numbers GSE25402 (transcriptomics of cohort 3) and GSE267800 (transcriptomics of siGLS versus siC transfected cells and single-nucleus RNA sequencing of *GLS<sup>AdipoqCre</sup>* and control mice). Metabolomics and clinical data from cohort 1 are provided in Petrus et al.<sup>7</sup> and Maqdasy et al.<sup>54</sup>. Additional data that support the findings of this study are available from the corresponding authors (N.M. and M.R.). Full individual clinical data are not publicly available due to them containing information that could compromise research participant privacy or consent. Source data are provided with this paper.

### Code availability

Scripts used for the analyses presented in this study are available at GitHub (<https://github.com/lmassier/GLS>).

### References

1. Felig, P., Marliss, E. & Cahill, G. F. Jr Plasma amino acid levels and insulin secretion in obesity. *N. Engl. J. Med.* **281**, 811–816 (1969).
2. Newgard, C. B. et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab.* **9**, 311–326 (2009).
3. Batista, T. M., Haider, N. & Kahn, C. R. Defining the underlying defect in insulin action in type 2 diabetes. *Diabetologia* **64**, 994–1006 (2021).
4. White, P. J. et al. Insulin action, type 2 diabetes, and branched-chain amino acids: a two-way street. *Mol. Metab.* **52**, 101261 (2021).
5. Ma, Q. X. et al. BCAA-BCKA axis regulates WAT browning through acetylation of PRDM16. *Nat. Metab.* **4**, 106–122 (2022).
6. Yoneshiro, T. et al. BCAA catabolism in brown fat controls energy homeostasis through SLC25A44. *Nature* **572**, 614–619 (2019).
7. Petrus, P. et al. Glutamine links obesity to inflammation in human white adipose tissue. *Cell Metab.* **31**, 375–390 e311 (2020).
8. Yoo, H. C., Yu, Y. C., Sung, Y. & Han, J. M. Glutamine reliance in cell metabolism. *Exp. Mol. Med.* **52**, 1496–1516 (2020).
9. Cheng, S. et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. *Circulation* **125**, 2222–2231 (2012).
10. Liu, X. et al. High plasma glutamate and low glutamine-to-glutamate ratio are associated with type 2 diabetes: case-cohort study within the PREDIMED trial. *Nutr. Metab. Cardiovasc. Dis.* **29**, 1040–1049 (2019).
11. Frayn, K. N., Khan, K., Coppack, S. W. & Elia, M. Amino acid metabolism in human subcutaneous adipose tissue in vivo. *Clin. Sci.* **80**, 471–474 (1991).
12. Wurtz, P. et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. *Diabetes Care* **36**, 648–655 (2013).
13. Yelamanchi, S. D. et al. A pathway map of glutamate metabolism. *J. Cell Commun. Signal* **10**, 69–75 (2016).
14. Armenise, C. et al. Transcriptome profiling from adipose tissue during a low-calorie diet reveals predictors of weight and glycemic outcomes in obese, nondiabetic subjects. *Am. J. Clin. Nutr.* **106**, 736–746 (2017).
15. Arner, E. et al. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. *Diabetes* **61**, 1986–1993 (2012).
16. Ryden, M. et al. Mapping of early signaling events in tumor necrosis factor-α-mediated lipolysis in human fat cells. *J. Biol. Chem.* **277**, 1085–1091 (2002).

17. Lukey, M. J., Greene, K. S., Erickson, J. W., Wilson, K. F. & Cerione, R. A. The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy. *Nat. Commun.* **7**, 11321 (2016).
18. Cheng, Y. et al. Prediction of adipose browning capacity by systematic integration of transcriptional profiles. *Cell Rep.* **23**, 3112–3125 (2018).
19. Pan, X. et al. Glutamine production by Glul promotes thermogenic adipocyte differentiation through Prdm9-mediated H3K4me3 and transcriptional reprogramming. *Diabetes* **72**, 1574–1596 (2023).
20. Taylor, C. T. & Scholz, C. C. The effect of HIF on metabolism and immunity. *Nat. Rev. Nephrol.* **18**, 573–587 (2022).
21. Hardie, D. G. AMPK—sensing energy while talking to other signaling pathways. *Cell Metab.* **20**, 939–952 (2014).
22. Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. *Cell* **168**, 960–976 (2017).
23. Schofield, C. J. & Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. *Nat. Rev. Mol. Cell Biol.* **5**, 343–354 (2004).
24. Kierans, S. J. & Taylor, C. T. Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology. *J. Physiol.* **599**, 23–37 (2021).
25. Carriere, A. et al. Browning of white adipose cells by intermediate metabolites: an adaptive mechanism to alleviate redox pressure. *Diabetes* **63**, 3253–3265 (2014).
26. Ahmed, K. et al. An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. *Cell Metab.* **11**, 311–319 (2010).
27. Lagarde, D. et al. Lactate fluxes and plasticity of adipose tissues: a redox perspective. *Front. Physiol.* **12**, 689747 (2021).
28. Yao, Z. et al. Dietary lactate supplementation protects against obesity by promoting adipose browning in mice. *J. Agric. Food Chem.* **68**, 14841–14849 (2020).
29. Wu, J. et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. *Cell* **150**, 366–376 (2012).
30. Kowalchuk, J. M., Curi, R. & Newsholme, E. A. Glutamine metabolism in isolated incubated adipocytes of the rat. *Biochem. J.* **249**, 705–708 (1988).
31. Cao, W. et al. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. *Mol. Cell. Biol.* **24**, 3057–3067 (2004).
32. Cao, W., Medvedev, A. V., Daniel, K. W. & Collins, S. beta-Adrenergic activation of p38 MAP kinase in adipocytes: cAMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase. *J. Biol. Chem.* **276**, 27077–27082 (2001).
33. Leiva, M., Matesanz, N., Pulgarin-Alfaro, M., Nikolic, I. & Sabio, G. Uncovering the role of p38 family members in adipose tissue physiology. *Front. Endocrinol.* **11**, 572089 (2020).
34. Robidoux, J. et al. Selective activation of mitogen-activated protein (MAP) kinase kinase 3 and p38alpha MAP kinase is essential for cyclic AMP-dependent UCP1 expression in adipocytes. *Mol. Cell. Biol.* **25**, 5466–5479 (2005).
35. Teruel, T., Hernandez, R., Benito, M. & Lorenzo, M. Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes. *J. Biol. Chem.* **278**, 263–269 (2003).
36. Nguyen, H. P. et al. Aifm2, a NADH oxidase, supports robust glycolysis and is required for cold- and diet-induced thermogenesis. *Mol. Cell* **77**, 600–617 e604 (2020).
37. Rabinowitz, J. D. & Enerback, S. Lactate: the ugly duckling of energy metabolism. *Nat. Metab.* **2**, 566–571 (2020).
38. Cai, X. et al. Lactate activates the mitochondrial electron transport chain independently of its metabolism. *Mol. Cell* **83**, 3904–3920 e3907 (2023).
39. Rosenwald, M., Perdikari, A., Rulicke, T. & Wolfrum, C. Bi-directional interconversion of brite and white adipocytes. *Nat. Cell Biol.* **15**, 659–667 (2013).
40. Cohen, P. & Kajimura, S. The cellular and functional complexity of thermogenic fat. *Nat. Rev. Mol. Cell Biol.* **22**, 393–409 (2021).
41. Cohen, P. et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. *Cell* **156**, 304–316 (2014).
42. Park, G. et al. Quantitative analysis of metabolic fluxes in brown fat and skeletal muscle during thermogenesis. *Nat. Metab.* **5**, 1204–1220 (2023).
43. Okamoto-Ogura, Y. et al. UCP1-dependent and UCP1-independent metabolic changes induced by acute cold exposure in brown adipose tissue of mice. *Metabolism* **113**, 154396 (2020).
44. Baghdadi, M., Mesaros, A., Purrio, M. & Partridge, L. Sex-specific effects of Cre expression in Syn1Cre mice. *Sci. Rep.* **13**, 10037 (2023).
45. Lindhorst, A., Bechmann, I. & Gericke, M. Unspecific DNA recombination in AdipoqCre-ER(T2) - mediated knockout approaches in transgenic mice is sex-, age- and genotype-dependent. *Adipocyte* **9**, 1–6 (2020).
46. Kowalski, T. J. & Watford, M. Production of glutamine and utilization of glutamate by rat subcutaneous adipose tissue in vivo. *Am. J. Physiol.* **266**, E151–E154 (1994).
47. Simon, J. et al. Targeting hepatic glutaminase 1 ameliorates non-alcoholic steatohepatitis by restoring very-low-density lipoprotein triglyceride assembly. *Cell Metab.* **31**, 605–622 e610 (2020).
48. Yu, W. et al. Targeting GLS1 to cancer therapy through glutamine metabolism. *Clin. Transl. Oncol.* **23**, 2253–2268 (2021).
49. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* **28**, 412–419 (1985).
50. Mileti, E. et al. Human white adipose tissue displays selective insulin resistance in the obese state. *Diabetes* **70**, 1486–1497 (2021).
51. Kolaczynski, J. W. et al. A new technique for biopsy of human abdominal fat under local anaesthesia with Lidocaine. *Int. J. Obes. Relat. Metab. Disord.* **18**, 161–166 (1994).
52. Rodbell, M. Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. *J. Biol. Chem.* **239**, 375–380 (1964).
53. Lofgren, P., Hoffstedt, J., Naslund, E., Wiren, M. & Arner, P. Prospective and controlled studies of the actions of insulin and catecholamine in fat cells of obese women following weight reduction. *Diabetologia* **48**, 2334–2342 (2005).
54. Maqdasy, S. et al. Impaired phosphocreatine metabolism in white adipocytes promotes inflammation. *Nat. Metab.* **4**, 190–202 (2022).
55. Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. *Sci. Rep.* **7**, 16878 (2017).
56. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).
57. Galarraga, M. et al. Adiposoft: automated software for the analysis of white adipose tissue cellularity in histological sections. *J. Lipid Res.* **53**, 2791–2796 (2012).
58. Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. *Gigascience* **9**, giaa151 (2020).
59. McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. *Cell Syst.* **8**, 329–337 e324 (2019).
60. Lopez, R., Regier, J., Cole, M. B., Jordan, M. I. & Yosef, N. Deep generative modeling for single-cell transcriptomics. *Nat. Methods* **15**, 1053–1058 (2018).
61. Hao, Y. et al. Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587 e3529 (2021).

62. Massier, L. et al. An integrated single cell and spatial transcriptomic map of human white adipose tissue. *Nat. Commun.* **14**, 1438 (2023).
63. Sarvari, A. K. et al. Plasticity of epididymal adipose tissue in response to diet-induced obesity at single-nucleus resolution. *Cell Metab.* **33**, 437–453 e435 (2021).
64. Canto, C. & Garcia-Roves, P. M. High-resolution respirometry for mitochondrial characterization of ex vivo mouse tissues. *Curr. Protoc. Mouse Biol.* **5**, 135–153 (2015).
65. Alexandersson, I., Harms, M. J. & Boucher, J. Isolation and culture of human mature adipocytes using membrane mature adipocyte aggregate cultures (MAAC). *J. Vis. Exp.* <https://doi.org/10.3791/60485> (2020).
66. Gullberg, J., Jonsson, P., Nordstrom, A., Sjostrom, M. & Moritz, T. Design of experiments: an efficient strategy to identify factors influencing extraction and derivatization of Arabidopsis thaliana samples in metabolomic studies with gas chromatography/mass spectrometry. *Anal. Biochem.* **331**, 283–295 (2004).
67. A, J. et al. Extraction and GC/MS analysis of the human blood plasma metabolome. *Anal. Chem.* **77**, 8086–8094 (2005).
68. Schauer, N. et al. GC-MS libraries for the rapid identification of metabolites in complex biological samples. *FEBS Lett.* **579**, 1332–1337 (2005).
69. Linden, P., Keech, O., Stenlund, H., Gardstrom, P. & Moritz, T. Reduced mitochondrial malate dehydrogenase activity has a strong effect on photorespiratory metabolism as revealed by <sup>13</sup>C labelling. *J. Exp. Bot.* **67**, 3123–3135 (2016).

## Acknowledgements

Adipose tissue biopsies from cohort 2 are part of the bariatric surgery cohort followed at CRNH, Pitie-Salpêtrière hospital (RHU-CARMMA Project), Paris, France. These samples were collected by L. Genser. We thank M. Björnholm for valuable input on the animal experiments. This work was supported by grants from Margareta af Ugglas foundation (M.R.), the Swedish Research Council (M.R., N.M., A.K. and J.R.Z. including establishing grants to S.M. and L.M.), ERC-SyG SPHERES (grant no. 856404 to M.R.), the Novo Nordisk Foundation (including the Tripartite Immuno-metabolism Consortium grant no. NNF15CC0018486, the MSAM consortium grant no. NNF15SA0018346 and the MeRIAD consortium grant no. 0064142, all three to M.R., MSAM and MeRIAD to A.K. and grant no. NNF20OC0061149 to N.M.), Knut and Alice Wallenberg's Foundation (A.K., M.R., T.M. and J.R.Z., including Wallenberg Clinical Scholar to M.R.), the Center for Innovative Medicine (S.M., N.M. and M.R.), the Swedish Diabetes Foundation (M.R.), the Stockholm County Council (M.R.), the Strategic Research Program in Diabetes at Karolinska Institutet (A.K. and M.R.), the Université Clermont Auvergne, Société Francophone du Diabète, Fondation Bettencourt Schueller (S.M.), and European Foundation for the Study of Diabetes (Rising star fellowship to S.M. and Future Leaders award to N.M.). French National Agency of Research (ANR-Captor to K.C.), Fondation pour la Recherche Médicale (grant nos. FDT201904008276, FDT202106012793 to K.C.) and Association Française d'Étude et de Recherche sur l'obésité (AFERO to S.L.). L.A. and M.O.H. are supported by postdoctoral fellowship from the strategic research program in diabetes at Karolinska Institutet. S.F.C. is supported by a Novo Nordisk postdoctoral fellowship run in partnership with Karolinska Institutet. L.M. was funded by a postdoctoral grant from the Swedish Society for Medical Research.

## Author contributions

S.L., S.M., N.M. and M.R. conceived the idea and wrote the manuscript, which was subsequently read, edited and approved by all co-authors. K.C. and M.R. collected clinical samples. S.L., S.M., D.R.-R., R.H., J.B.A., G.M., K.C. and A.K. designed and performed studies in mice. G.R., D.S.Z. and L.M. performed bioinformatic analyses. J.Z. and J.J. performed the single-nucleus RNA sequencing experiments. S.L., S.M., G.R., I.V., L.M.A., R.H. M.O.-H., F.M., E.-J.E.H., C.R., S.F.-C., T.d.C.B. and M.L.-Y. performed in vitro assays. O.H., M.J. and T.M. performed the targeted metabolite analyses. M.O.B., P.P., J.R.Z. and K.C. contributed to data analyses and interpretation. S.L. and S.M. put together all source data.

## Funding

Open access funding provided by Karolinska Institute.

## Competing interests

The authors declare no competing interests.

## Additional information

**Extended data** is available for this paper at <https://doi.org/10.1038/s42255-024-01083-y>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s42255-024-01083-y>.

**Correspondence and requests for materials** should be addressed to Niklas Mejhert or Mikael Rydén.

**Peer review information** *Nature Metabolism* thanks Mariia Yuneva and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editors: Christoph Schmitt and Isabella Samuelson, in collaboration with the *Nature Metabolism* editorial team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).


**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024


<sup>1</sup>Department of Medicine (Huddinge), Karolinska Institutet, ME Endokrinologi, Karolinska University Hospital Huddinge, Huddinge, Sweden. <sup>2</sup>Nutrition and Obesity: Systemic Approaches Research Group, NutriOmics, Sorbonne Université, INSERM, Paris, France. <sup>3</sup>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. <sup>4</sup>Swedish Metabolomics Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, Umeå, Sweden. <sup>5</sup>The Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. <sup>6</sup>Adipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit,

University Hospital Miguel Servet, Zaragoza, Spain. <sup>7</sup>Instituto Aragonés de Ciencias de La Salud (IACS), Zaragoza, Spain. <sup>8</sup>Instituto de Investigación Sanitaria (IIS)-Aragón, Zaragoza, Spain. <sup>9</sup>Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden. <sup>10</sup>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. <sup>11</sup>Nutrition Department, Assistance Publique Hôpitaux de Paris, CRNH Ile-de-France, Pitié-Salpêtrière Hospital, Paris, France. <sup>12</sup>These authors contributed equally: Simon Lecoutre, Salwan Maqdasy, David Rizo-Roca. <sup>13</sup>These authors jointly supervised this work: Niklas Mejhert, Mikael Rydén. ✉e-mail: [niklas.mejhert@ki.se](mailto:niklas.mejhert@ki.se); [mikael.ryden@ki.se](mailto:mikael.ryden@ki.se)



**Extended Data Fig. 1 | Glutamine turnover is altered in WAT of men and women with obesity.** **a.** Plasma ( $n = 53$ , the two panels to the left) and subcutaneous white adipose tissue ( $n = 26$ , the two panels to the right) glutamine and glutamate levels compared between individuals living with or without (w/o) obesity. The log values of glutamine levels in WAT and plasma have previously been published in<sup>7</sup>. Data were analyzed by Student's  $t$ -test or the Mann-Whitney


U test, depending on the distribution, and  $p$  values are shown. Error bars are S.E.M. **b.** Results from publicly available RNA-seq data (GSE95640)<sup>14</sup> summarizing the expression of *GLS* (left panel) and *GLUL* (right panel) in subcutaneous white adipose tissue from men living with ( $n = 55$ ) or w/o obesity ( $n = 10$ ) and women living with ( $n = 101$ ) or w/o ( $n = 14$ ) obesity. Data were analyzed by Wilcoxon rank sum test and  $p$  values are shown. Box plots display min, max, and median.



### Extended Data Fig. 2 | TNF $\alpha$ promotes glutaminolysis in white adipocytes.

**a.** Pathway analysis of genes positively associated with *GLS* mRNA expression and negatively associated with *GLUL* mRNA expression. The size of the dots is proportional to the Gene Set Enrichment Analysis score. **b.** Correlation between *GLUL/GLS* mRNA expression and TNF $\alpha$  secretion *ex vivo* in human subcutaneous adipose tissue in cohort 3 ( $n = 45$ ).  $r$ - and  $p$  values are shown for correlation using simple Pearson's regression analysis. **c.** Freshly isolated human adipocytes were cultured with or without TNF $\alpha$  for 24 hrs. Analyses of gene expression by qPCR (six replicates per condition, repeated >three times) (left) and glutamine and glutamate levels including glutamine-to-glutamate ratio (six and five replicates per condition) in conditioned media (right) were performed. Data were analyzed by Student's  $t$ -test and  $p$  values are shown. **d.** Analyses of gene expression by qPCR in human adipocytes incubated with vehicle ( $n = 8$ ), TNF $\alpha$  ( $n = 4$ ), isoprenaline ( $n = 4$ ) or insulin ( $n = 4$ ). Data were compared using one-way ANOVA with Dunnett's post-hoc test and  $p$  values are shown (experiment repeated >three times). **e.** Representative examples of protein levels of GLS and


the inflammatory pathways induced by TNF $\alpha$  (JNK, STAT3 and NF $\kappa$ B) in human adipocytes incubated with TNF $\alpha$  for four hours with or without inhibitors of each pathway (repeated two times). Proteins from the same samples were loaded on three different gels in parallel. **f.** Chromatin immunoprecipitation followed by qPCR analysis showing that c-Jun binds to the human *GLS* promoter. Complexes containing c-Jun were immunoprecipitated from cross-linked and digested chromatin isolated from human adipocytes incubated with PBS or TNF $\alpha$ . Following reversal of cross-links and purification of DNA, qPCR was run using primers designed to amplify a 196-bp fragment centered around the putative c-Jun binding site at position -247 to -125 bp relative to the transcriptional start site (TSS). The data presented are the relative quantity values from independent duplicate reactions. Data in panels **c-d** show mean  $\pm$  S.E.M. **Abbreviations:** TNF $\alpha$  = Tumor necrosis factor alpha, TG = triglycerides, -insulin = cells deprived from insulin for 24 hours, +insulin = insulin treatment for six hours, isoprenaline = isoprenaline treatment for six hours.



Extended Data Fig. 3 | See next page for caption.


**Extended Data Fig. 3 | GLS depletion promotes metabolic gene programs independently of effects on adipogenesis. a-c.** *In vitro* differentiated human adipocytes were transfected with siC or siGLS. Effects on (a) gene expression (four replicates per condition, repeated >three times), (b) protein abundance (repeated twice) of adipogenic markers (left) and adiponectin secretion (in total sixteen replicates per condition from two independent experiments) (right) and (c) lipid droplet morphology (repeated >three times) were determined. Scale bar in panel c = 20  $\mu$ m. Proteins from the same samples were loaded on four different gels in parallel. d. Gene set enrichment analysis listing the top five pathways altered in siGLS vs. siC human adipocytes. e. Heatmaps of indicated pathways and genes altered in siGLS vs. siC treated human adipocytes. f. Representative examples of electron transport chain (ETC) protein levels in human adipocytes

incubated with 0, 2.5 and 10 mmol/L of glutamine. Cells were either deprived or treated with indicated concentrations of glutamine for 48 hours (repeated three times). Proteins from the same samples were loaded on two different gels in parallel. g. Representative examples of ETC protein levels in human adipocytes transfected with siC or siGLS oligonucleotides incubated with or without  $\alpha$ -ketoglutarate (E $\alpha$ KG, repeated three times). h. Representative examples of ETC protein levels in human adipocytes transfected with siC or siGLS oligonucleotides and with scrambled mRNA or over expressing GLS mRNA. (repeated two times). Error bars in panels a-b are S.E.M. **Abbreviations:** ADIPOQ = adiponectin, BODIPY = boron-dipyrromethene, CEBPA = CCAAT/enhancer-binding protein alpha, PLIN1 = Perilipin 1, PPAR $\gamma$  = peroxisome proliferator-activated receptor gamma.



**Extended Data Fig. 4 | Glycolytic activity drives oxygen consumption rates following GLS depletion.** **a.** Oxygen consumption rates (OCR) during mitostress tests in siC or siGLS human adipocytes co-transfected with siC or siUCP1 (left). Data (six replicates per condition, repeated two times) were compared for basal and maximal respiratory capacity. Results were compared using two-way ANOVA and Tukey's post-hoc test and  $p$  values are shown (right). **b.** OCR during mitostress tests in siC or siGLS human adipocytes incubated with or without glutamine for 48 hours (left). Data were compared for basal and maximal respiratory capacity. Results were compared using two-way ANOVA and Tukey's post-hoc test and the  $p$  value is shown (right) (six replicates per condition, repeated three times). **c.** OCR during mitostress tests in siC or siGLS human adipocytes (left) incubated with or without glucose. Data were compared for basal and maximal respiratory capacity. Results were compared using two-way ANOVA and Tukey's post-hoc test and  $p$  values are shown (right) (six replicates per condition, repeated two times). **d.** OCR during mitostress tests in siC or


siGLS human adipocytes (left) incubated with or without 2-deoxy-D-glucose (2DG). Data were compared for basal and maximal respiratory capacity. Results were compared using two-way ANOVA and Tukey's post-hoc test and  $p$  values are shown (right) (six replicates per condition, repeated two times). **e.** OCR during mitostress tests in siC or siGLS human adipocytes (left) incubated with or without UK5099. Data (repeated two times) were compared for basal and maximal respiratory capacity. Results were compared using two-way ANOVA and Tukey's post-hoc test and  $p$  values are shown (right) (six replicates per condition, repeated two times). **f.** OCR during mitostress tests in siC or siGLS human adipocytes (left) incubated with or without sodium pyruvate. Data (repeated two times) were compared for basal and maximal respiratory capacity. Results were compared using two-way ANOVA and Tukey's post-hoc test and  $p$  values are shown (right) (six replicates per condition, repeated two times). Data in all panels show mean  $\pm$  S.E.M. **Abbreviations:** FCCP = carbonylcyanide-*p*-trifluoromethoxy phenylhydrazone, O = oligomycin, R/A = rotenone/antimycin A.



**Extended Data Fig. 5 | Pharmacologic inhibition of GLS induces oxidative activity.** **a.** Effects of BPTES on glutamate labeling using  $^{13}\text{C}$ -labeled glutamine (three replicates per condition). **b-e.** Effect of BPTES on **(b)** glucose-6-phosphate (G6P), pyruvate and lactate levels, **(c)** electron transport chain, UCP1 and GLS protein levels (three replicates per condition), **(d)** oxygen consumption rates (OCR) (six replicates per condition, repeated >three times) and **(e)** extracellular acidification rates (ECAR) in human adipocytes (six replicates per condition, repeated three times). In panel **c**, the proteins from the same samples were loaded on two different gels in parallel. **f.** Effects of CB-839 on primary human


mature adipocytes ( $n = 12$  from two independent experiments) on gene expression of mitochondrial markers. **g.** Effects of CB-839 in human mature adipocytes on protein expression of electron transport chain proteins (repeated two times). Data in **a**, **b**, **f** were compared using Student's  $t$ -test and  $p$  values are shown. Data in **d**, **e** were compared using two-way ANOVA and  $p$  values reflecting treatment effects are shown. Data in panels **a-b** and **d-f** show mean  $\pm$  S.E.M.

**Abbreviations:** 2DG = 2-Deoxy-D-glucose, DMSO = dimethyl sulfoxide, FCCP = carbonylcyanide- $p$ -trifluoromethoxyphenylhydrazone, O = oligomycin, R/A = rotenone/antimycin A.



**Extended Data Fig. 6 | Links between GLS depletion and oxygen consumption.** **a.** Western blot of global protein O-GlcNAcylation in siC or siGLS human adipocytes. Representative results are displayed (repeated two times). **b.** Expression of indicated *PRDM* genes in siC or siGLS human adipocytes based on RNA-seq data from human adipocytes transfected with siC or siGLS (three replicates per condition). **c.** The mTORC1 activity (left panel) in siC or siGLS human adipocytes was assessed by western blot analysis. This was performed by treating cells with or without an mTORC1 activator (insulin, 15 minutes treatment), and by additionally treating with or without an mTORC1 inhibitor (rapamycin) for three hours in insulin-deprived cells (repeated three times). The AMPK activity (right panel) in human adipocytes subjected to siC or siGLS was assessed through western blot analysis. Cells were incubated cells with or without an AMPK activator (PF739) for 24 hours (repeated two times). Proteins from the same experiments were loaded on two different gels in parallel for the panels on the left and on two different gels for the panels on the right. **d.** Oxygen consumption rates during mitostress tests in siC or siGLS human adipocytes

(left) incubated with or without eta-ketoglutarate (EtaKG). Data were compared for basal respiration and maximal respiratory capacity (six replicates per condition, repeated two times). Data were compared using two-way ANOVA and Tukey's post-hoc test, *p* values are shown (right). **e.** Oxygen consumption rates during mitostress test in human adipocytes incubated with a GPR1 agonist (six replicates per condition, repeated two times). **f.** Representative examples of ETC protein levels in human adipocytes incubated with GPR1 agonist (two replicates per condition, repeated two times). **g.** NAD<sup>+</sup>, NADH and the ratio in siC or siGLS human adipocytes (four replicates per condition, repeated two times). **h.** Representative examples of ETC protein and P38 MAPK pathway levels in human adipocytes incubated with lactate for 30 minutes (repeated three times). Proteins from the same samples were loaded on two different gels in parallel. **i.** Oxygen consumption rates during mitostress test in human adipocytes incubated with sodium lactate (six replicates per condition, repeated two times). Data were compared using Student's *t*-test and *p* values are shown (right). Data in panels **d-e, g, i** show mean ± S.E.M.



Extended Data Fig. 7 | See next page for caption.

**Extended Data Fig. 7 | Cross-talk between high fat diet and glutamine metabolism in male and female mice.** **a.** *Gls* and *Glut* mRNA expression in different adipose depots in male or female mice fed chow (CD) or high fat diet (HFD) for 15 weeks (seven male mice and four female mice per condition). Data were compared using Student's *t*-test and *p* values are shown. **b.** Glutamine (gln) and glutamate (glu) levels including glutamine-to-glutamate ratio were measured in the plasma (left) or iWAT (right) of male and female mice fed chow (CD) or high fat diet (HFD) for 15 weeks (four mice per gender and per condition). Data were compared using Student's *t*-test and *p* values are shown. **c.** Expression of genes encoding UCP1 and electron transport chain proteins in iWAT of mice fed chow (CD-vehicle, *n* = 8) or HFD injected intraperitoneally with either vehicle (HF-vehicle, *n* = 12) or glutamine (HF-GLN, *n* = 12) for two weeks. This cohort of mice has been described before<sup>7</sup>. Data were compared using one-way ANOVA and

Tukey's post-hoc test, *p* values are shown. **d.** Ct values of *Cre* (left) and *Gls* mRNA expression (right) in mature adipocytes from eWAT or iWAT of *Gls*<sup>fl/fl</sup> (*n* = 3) and *Gls*<sup>AdipoqCre</sup> (*n* = 4) female mice. **e.** Expression of HIF1 $\alpha$  target genes in iWAT of *Gls*<sup>fl/fl</sup> (*n* = 8) and *Gls*<sup>AdipoqCre</sup> (*n* = 5) male mice. Data were analyzed by Student's *t*-test and *p* values are shown. **f.** Food intake (left) and locomotor activity (right) in *Gls*<sup>fl/fl</sup> (*n* = 8) and *Gls*<sup>AdipoqCre</sup> (*n* = 5) male mice. Data (eight and five mice per condition) were analyzed by two-way ANOVA with no statistical significance detected. Data presented in box plot represent min., max and median. Data in panels **a-e** show mean  $\pm$  S.E.M. **Abbreviations:** Ct = threshold cycles, *Cre* = Cre recombinase-mediated DNA recombination, eWAT = epididymal white adipose tissue, iWAT = inguinal white adipose tissue, MA = mature adipocytes, ND = non-detectable.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a                                 | Confirmed  |
|-------------------------------------|--|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of all covariates tested   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated   |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection	No software was used for data collection
Data analysis	Image Lab 6.0.1 GraphPad Prism 7.0 and 9.5.0 RStudio v4.1.1 and v4.2.1 ImageJ 1.45 software NIST MR 2.2 CASAVA 1.8.2 JMP v15.1 Scripts used for the analyses presented in this study are available at GitHub ( <a href="https://github.com/lmassier/GLS">https://github.com/lmassier/GLS</a> ).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Data generated or retrospectively analyzed in this study are publicly available in the NCBI Gene Expression Omnibus repository under the accession numbers GSE25402 (transcriptomics of cohort 3) and GSE267800 (transcriptomics of siGLS vs. siC transfected cells and snSeq of GLsAdipoqCre and control mice). Metabolomics data from cohort 1 are provided in Petrus et al. and Maqdasy et al. (refs 7 and 54 in the manuscript) Source data for western blots are provided with this paper.

## Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	The sex of all participants is detailed in the manuscript.
Reporting on race, ethnicity, or other socially relevant groupings	In Sweden and France we are not allowed to ask for race or ethnicity in clinical studies.
Population characteristics	Characteristics of the clinical cohorts are provided in Supplementary Table 1
Recruitment	No recruitment was done for the present study, participants were included as described in the original publications.
Ethics oversight	All studies were approved by the regional ethics boards in Stockholm (cohort 1 and 3) and Paris (cohort 2), and informed written consent was obtained from all study participants. Cohort 1 is part of NCT01727245 and cohort 2 is part of several studies (NCT00476658, NCT01655017, NCT01454232) registered at clinicaltrials.gov.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	All cohorts included in this study have already been presented previously. No power calculation was performed but the clinical data was reproduced in three independent cohorts from two different countries. The experiments in vitro were repeated at least two-three times using several technical replicates. Finally, for the mouse studies, data are based on at least four animals per group and condition and were reproduced in two different laboratories using orthogonal approaches.
Data exclusions	Possible outliers were identified by “boxplot.stats” with default parameters in R.
Replication	As described above, results were replicated via independent experiments and studies. These included in vitro validation in adipocytes; by in vivo validation utilizing both genetic and pharmacological methodologies; and by analyses in independent clinical cohorts. Furthermore, the reliability and reproducibility of the findings were ensured as all key experiments were independently replicated more than three times, with details regarding the number of independent replications provided in the figure legends.
Randomization	Randomization was not applicable due to the inclusion of samples from participant with diverse medical conditions (i.e with or without obesity) and the analysis of existing data without intervention.
Blinding	The technicians performing the isolation and preparation of the samples were blinded to the group to which the sample belonged.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

## Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

Antibodies used	All antibodies are detailed in Supplementary Table 2 including the relevant dilutions.
Validation	All antibodies used in this study are commercially available and have been validated by the respective manufacturer. In addition, we further validated their specificity by western blot showing bands of the expected molecular sizes that were depleted upon gene depletion/knockout or increased upon over expression, respectively.

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)	We use mesenchymal stem cells derived from human white adipose tissue as detailed in the manuscript, see reference 7 in the manuscript. HEK293 cells were purchased from ATCC. Primary murine cells were freshly isolated in the laboratory and immediately utilized for experiments.
Authentication	HEK293 cells were validated by ATCC, while primary cells, including mesenchymal stem cells for efficient adipogenesis and primary adipocytes for adipokine secretion and lipolysis, were authenticated in the laboratory. Authentication primarily relied on morphological characteristics and functional assays (adipokine secretion by ELISA, lipolysis assay).
Mycoplasma contamination	We regularly test for mycoplasma contamination and only use cells that are mycoplasma-free.
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	No commonly misidentified cell lines were used.

## Animals and other research organisms

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	C57/Bl6 were used throughout the study. Adiponectin-Cre mice were crossed with Glsfl/fl mice (stock 017894, Glstm2.1Sray/J) to generate adipocyte-specific Gls-depleted mice (GlsAdipoq-Cre). Male mice aged five to fifteen weeks were utilized for the experiments. The mice were group-housed in ventilated cages maintaining a 12-hour light/12-hour dark cycle with lights on from 06:00 to 18:00. The facilities maintained a temperature range of 20-24°C and 50% humidity, with mice having ad libitum access to food and water.
Wild animals	No wild animals were used in the study.
Reporting on sex	Data in male and female mice are presented in the manuscript.
Field-collected samples	No field collected samples were used in the study.
Ethics oversight	Ethical animal board in Stockholm and Paris, respectively

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	Cohort 1 is part of a study registered at clinicaltrials.gov as NCT01727245, and cohort 2 includes samples from studies registered in
-----------------------------	---

Clinical trial registration	the same database under NCT00476658, NCT01655017, NCT01454232. Please note that the metabolomics data from cohort 1 have been published and the relevant references are provided in the paper (refs 7 and 54).
Study protocol	NCT01727245 studied the effect of bariatric surgery in people living with obesity compared with non-obese controls. Only baseline data are provided here.
Data collection	N/a
Outcomes	Outcomes are described under the respective accession numbers at <a href="https://clinicaltrials.gov">clinicaltrials.gov</a> .

## Plants

---

Seed stocks	N/a
Novel plant genotypes	N/a
Authentication	N/a